## HEALTH EFFECTS ASSESSMENT FOR METHYLENE CHLORIDE

ENVIRONMENTAL CRITERIA AND ASSESSMENT OFFICE OFFICE OF HEALTH AND ENVIRONMENTAL ASSESSMENT OFFICE OF RESEARCH AND DEVELOPMENT U.S. ENVIRONMENTAL PROTECTION AGENCY CINCINNATI, OH 45268

# HEALTH EFFECTS ASSESSMENT FOR METHYLENE CHLORIDE

ENVIRONMENTAL CRITERIA AND ASSESSMENT OFFICE OFFICE OF HEALTH AND ENVIRONMENTAL ASSESSMENT OFFICE OF RESEARCH AND DEVELOPMENT U.S. ENVIRONMENTAL PROTECTION AGENCY CINCINNATI, OH 45268

| TECHNICAL REPORT DATA (Please read Instructions on the reverse before completing) |                                       |  |  |  |  |  |  |
|---|---------------------------------------|--|--|--|--|--|--|
| EPA/600/8-89/092  | 3. RECIPIENT'S ACCESSION NO           |  |  |  |  |  |  |
|   | PB90-142449/AS                        |  |  |  |  |  |  |
| 4. TITLE AND SUBTITLE   | S. REPORT DATE                        |  |  |  |  |  |  |
| Updated Health Effects Assessment for Methylene                                   |                                       |  |  |  |  |  |  |
| Chloride  | S. PERFORMING ORGANIZATION CODE       |  |  |  |  |  |  |
| 7. AUTHOR(S)  | S. PERFORMING ORGANIZATION REPORT NO. |  |  |  |  |  |  |
| 9. PERFORMING ORGANIZATION NAME AND ADDRESS                                       | 10. PROGRAM ELEMENT NO.               |  |  |  |  |  |  |
|   | 11. CONTRACT/GRANT NO.                |  |  |  |  |  |  |
| 12. SPONSORING AGENCY NAME AND ADDRESS  | 13. TYPE OF REPORT AND PERIOD COVERED |  |  |  |  |  |  |
| Environmental Criteria and Assessment Office                                      | 14. SPONSORING AGENCY CODE            |  |  |  |  |  |  |
| Office of Research and Development  | i                                     |  |  |  |  |  |  |
| U.S. Environmental Protection Agency  | EPA/600/22                            |  |  |  |  |  |  |
| Cincinnati OH 45268   |                                       |  |  |  |  |  |  |

#### 16. ABSTRACT

This report summarizes and evaluates information relevant to a preliminary interim assessment of adverse health effects associated with specific chemicals or compounds. The Office of Emergency and Remedial Response (Superfund) uses these documents in preparing cost-benefit analyses under Executive Order 12991 for decision-making under CERCLA. All estimates of acceptable intakes and carcinogenic potency presented in this document should be considered as preliminary and reflect limited resources allocated to this project. The intent in these assessments is to suggest acceptable exposure levels whenever sufficient data are available. The interim values presented reflect the relative degree of hazard associated with exposure or risk to the chemical(s) addressed. Whenever possible, two categories of values have been estimated for systemic toxicants (toxicants for which cancer is not the endpoint of concern). The first, RfDc or subchronic reference dose, is an estimate of an exposure level that would not be expected to cause adverse effects when exposure occurs during a limited time interval. The RfD is an estimate of an exposure level that would not be expected to cause adverse effects when exposure occurs for a significant portion of the lifespan. For compounds for which there is sufficient evidence of carcinogenicity, q1\*s have been computed, if appropriate, based on oral and inhalation data if available.

| 7. KEY WORDS AND DOCUMENT ANALYSIS |   |                      |  |  |  |  |
|------------------------------------|---|----------------------|--|--|--|--|
| DESCRIPTORS                        | b.IDENTIFIERS/OPEN ENDED TERMS              | c. COSATI Fæld/Group |  |  |  |  |
|                                    |   |                      |  |  |  |  |
|                                    |   |                      |  |  |  |  |
|                                    |   |                      |  |  |  |  |
|                                    |   |                      |  |  |  |  |
|                                    |   |                      |  |  |  |  |
| . DISTRIBUTION STATEMENT           | 19. SECURITY CLASS (This Report)            | 21. NO. OF PAGES     |  |  |  |  |
| Public                             | Unclassified                                |                      |  |  |  |  |
| . 40116                            | 20. SECURITY CLASS (This page) Unclassified | 22. PRICE            |  |  |  |  |

EPA Form 2220-1 (Rev. 4-77) PREVIOUS EDITION IS OBSOLETE

# ORD CLEARANCE FORM

| 1. EPA Report No.  | 2. Series  | 3. Lab/Office Draft No.  | Lab/Office Draft No. 4 Copyright Permission  |  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|--|--|--|
|  | EPA/600/8  | ECAO-Cin-HO28a   | - Copyright Parmission   |  |  |  |  |  |  |  |
|  |  |  | ☐ Yes (Attached) ☐ No 戊N/A   |  |  |  |  |  |  |  |
| 5A. Original Document Title: Updated Health E  58. Final Document Title, if che                                      |  | or Methylene Chloride  |  |  |  |  |  |  |  |  |
| 6. Author(s), Affiliation, and Add<br>EPA authors with Lab/Offic   | · ·  | 7. Project Officer/FTS Telepho<br>Chris DeRosa<br>U.S. EPA/ECAO-Cin<br>8. Contract/IAG/Assistance A  | 684-7534   |  |  |  |  |  |  |  |
|  |  | 9. Product (check one)   |  |  |  |  |  |  |  |  |
| 10. DU/Obj./PPA/Project/Deli   | versble Output No.   | ☐ Peer Reviewed Journal Ar   | Cicle (complete blood 40)  |  |  |  |  |  |  |  |
| Signature of sender (if other 12. Signature/Date  Denuty J. Au  Document Manager  Branch Uniter                      | Chan Plan Date to CEI  than THPIMI Date to CEI  than 3/31/ | Published Reports: Project floppy diskettes), Method Design Manual, Handb Assessment Document Proceedings (Conferences Symposium Papers and Bit Internal Report (distributed Design Papers and Bit Internal Report | t Report/Summary (magnetic tapes/d. Research Report, User's Guide, 100k, Criteria Document, Health t. Technology Transfer Report, 15. Symposia, Workshops) 100k Chapters 101 restricted to EPA) 101. research brief, trade paper) non-icle (complete block 13) 102. dude Month/Year) |  |  |  |  |  |  |  |
|  |  | 14. Distribution (use block 16   | vif Necessary)   |  |  |  |  |  |  |  |
| 15A. This Publication  does not have policy implicated has policy implications for Efferment attached)  16. Comments | ions for EPA   | Director OHEA  | Inland 15C. Date 10/19/89  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |

#### DISCLAIMER

This document has been reviewed in accordance with the U.S. Environmental Protection Agency's peer and administrative review policies and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

#### PREFACE

This report summarizes and evaluates information relevant to a preliminary interim assessment of adverse health effects associated with methylene chloride. All estimates of acceptable intakes and carcinogenic potency presented in this document should be considered as preliminary and reflect limited resources allocated to this project. Pertinent toxicologic and environmental data were located through on-line literature searches of the TOXLINE, CANCERLINE and the CHEMFATE/DATALOG data bases. The basic literature searched supporting this document is current up to May, 1987. Secondary sources of information have also been relied upon in the preparation of this report and represent large-scale health assessment efforts that entail extensive peer and Agency review. The following Office of Health and Environmental Assessment (OHEA) sources have been extensively utilized:

- U.S. EPA. 1980a. Ambient Water Quality Criteria Document for Halomethanes. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Water Regulations and Standards, Washington, DC. EPA-440/5-80-051. NTIS PB 81-117624.
- U.S. EPA. 1982. Errata: Halomethanes Ambient Water Quality Criteria for the Protection of Human Health. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Water Regulations and Standards, Washington, DC.
- U.S. EPA. 1983. Reportable Quantity for Dichloromethane. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Emergency and Remedial Response, Washington, DC.
- U.S. EPA. 1985a. Health Assessment Document for Dichloromethane (Methylene Chloride). Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Research Triangle Park, NC. EPA-600/8-82-004F. NTIS PB 85-191559.
- U.S. EPA. 1985b. Addendum to the Health Assessment Document for Dichloromethane (Methylene Chloride): Updated Carcinogen Assessment of Dichloromethane (Methylene Chloride). Office of Health and Environmental Assessment, Carcinogen Assessment Group, Washington, DC.
- U.S. EPA. 1986c. Integrated Risk Information System (IRIS). Carcinogenicity Assessment for Lifetime Exposure to Methylene Chloride. Online. (Verification date 12/04/86.) Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH.

The intent in these assessments is to suggest acceptable exposure levels for noncarcinogens and risk cancer potency estimates for carcinogens whenever sufficient data were available. Values were not derived nor were larger uncertainty factors employed when the variable data were limited in scope tending to generate conservative (i.e., protective) estimates. Nevertheless, the interim values presented reflect the relative degree of hazard or risk associated with exposure to the chemical(s) addressed.

Whenever possible, two categories of values have been estimated for systemic toxicants (toxicants for which cancer is not the endpoint of concern). The first, RfDs (formerly AIS) or subchronic reference dose, is an estimate of an exposure level that would not be expected to cause adverse effects when exposure occurs during a limited time interval (i.e., for an interval that does not constitute a significant portion of the lifespan). This type of exposure estimate has not been extensively used, or rigorously defined, as previous risk assessment efforts have been primarily directed towards exposures from toxicants in ambient air or water where lifetime exposure is assumed. Animal data used for RFDs estimates generally include exposures with durations of 30-90 days. Subchronic human data are rarely available. Reported exposures are usually from chronic occupational exposure situations or from reports of acute accidental exposure. These values are developed for both inhalation (RfDsI) and oral (RfDsO) exposures.

The RfD (formerly AIC) is similar in concept and addresses chronic exposure. It is an estimate of an exposure level that would not be expected to cause adverse effects when exposure occurs for a significant portion of the lifespan [see U.S. EPA (1980b) for a discussion of this concept]. The RfD is route-specific and estimates acceptable exposure for either oral (RfD $_0$ ) or inhalation (RfD $_1$ ) with the implicit assumption that exposure by other routes is insignificant.

Composite scores (CSs) for noncarcinogens have also been calculated where data permitted. These values are used for identifying reportable quantities and the methodology for their development is explained in U.S. EPA (1984).

For a discussion of risk assessment methodology for carcinogens refer to U.S. EPA (1980b). Since cancer is a process that is not characterized by a threshold, any exposure contributes an increment of risk. For carcinogens,  $q_1 *s$  have been computed, if appropriate, based on oral and inhalation data if available.

#### **ABSTRACT**

In order to place the risk assessment evaluation in proper context, refer to the preface of this document. The preface outlines limitations applicable to all documents of this series as well as the appropriate interpretation and use of the quantitative estimates presented.

The major issue of concern is the amply demonstrated carcinogenicity of methylene chloride. Although human data are lacking, animal experiments have clearly demonstrated the carcinogenicity of methylene chloride in mice and strongly suggest carcinogenicity in rats. Methylene chloride has been shown to be mutagenic in <u>Salmonella</u> and to increase the number of chromosomal aberrations in cultured chinese hamster ovary cells.

The U.S. EPA (1985b, 1986c) reported an oral unit risk slope estimate of  $7.5 \times 10^{-3}$  (mg/kg/day)<sup>-1</sup> based on the arithmetic mean of slope factors derived from the NTP (1985) inhalation data and the NCA (1983) oral data. The U.S. EPA (1985b, 1986c) also reported an inhalation unit risk slope estimate of  $1.4 \times 10^{-2}$  (mg/kg/day)<sup>-1</sup> based on the combined incidence of carcinomas and adenomas of the lung or liver in B6C3f1 mice from the 2-year NTP (1985) inhalation study. The corresponding unit risk for air is given as  $4.1 \times 10^{-6}$  µg/m³. In all of these analyses methylene chloride has been classified in weight of the evidence category B2, probable human carcinogen. A potential revision to the unit risk estimate has been proposed based upon the application of pharmacokinetic modeling (U.S. EPA, 1987). Adoption of a unit risk estimate based upon pharmacokinetic modeling could lead to an estimate 1 to 2 orders of magnitude lower than that currently proposed.

#### **ACKNOWLEDGEMENTS**

The initial draft of this report was prepared by Syracuse Research Corporation under Contract No. 68-03-3112 for EPA's Environmental Criteria and Assessment Office, Cincinnati, OH. Dr. Christopher DeRosa and Karen Blackburn were the Technical Project Monitors and Helen Ball was the Project Officer. The final documents in this series were prepared for the Office of Emergency and Remedial Response, Washington. DC.

Scientists from the following U.S. EPA offices provided review comments for this document series:

Environmental Criteria and Assessment Office, Cincinnati, OH Carcinogen Assessment Group Office of Air Quality Planning and Standards Office of Solid Waste Office of Toxic Substances Office of Drinking Water

Editorial review for the document series was provided by the following:

Judith Olsen and Erma Durden Environmental Criteria and Assessment Office Cincinnati, OH

Technical support services for the document series, was provided by the following:

Bette Zwayer, Trina Porter Environmental Criteria and Assessment Office Cincinnati, OH

# TABLE OF CONTENTS

|     |                      |                                  |                              |                         |        |     |     |       |     |     |      |     |     |    |      |     |          |   |   |   |   |    |   | Page           |
|-----|----------------------|----------------------------------|------------------------------|-------------------------|--------|-----|-----|-------|-----|-----|------|-----|-----|----|------|-----|----------|---|---|---|---|----|---|----------------|
| ١.  | ENVIRO               | NMENTAL C                        | HEMIST                       | RY AND                  | F      | ATE | Ξ.  | •     | •   | •   |      |     | •   | •  |      |     |          | • | • | • |   | •  |   | 1              |
| 2.  | ABSORP               | TION FACT                        | ORS IN                       | HUMAN                   | S      | ANE | ) E | Χſ    | PER | lI  | 1E N | NT/ | \L  | Al | NI P | 1AL | .s       |   | • | • | • |    |   | 4              |
|     | 2.1.                 | ORAL<br>INHALATI                 |                              |                         |        |     |     |       |     |     |      |     |     |    |      |     |          |   |   |   |   |    |   | 4 5            |
| 3.  | TOXICI               | TY IN HUM                        | ANS ANI                      | D EXPE                  | RI     | MEN | IT/ | ۱L    | AN  | I   | IAL  | .s  |     |    | •    | •   |          | • |   |   |   |    | • | 8              |
|     | 3.1.                 | SUBCHRON                         | IC                           |                         |        | •   | •   |       | •   | •   |      | •   | •   |    | •    | •   |          | • |   |   |   | •  |   | 8              |
|     |                      |                                  | Oral.<br>Inhala              |                         |        |     |     |       |     |     |      |     |     |    |      |     |          |   |   |   |   |    |   | 8<br>9         |
|     | 3.2.                 | CHRONIC.                         |                              |                         | •      |     | •   |       |     |     | •    | •   | •   | •  |      | •   |          |   |   | • |   |    |   | 12             |
|     |                      | 3.2.1.<br>3.2.2.                 |                              |                         |        |     |     |       |     |     |      |     |     |    |      |     |          |   |   |   |   |    |   | 12<br>12       |
|     | 3.3.                 | TERATOGE                         | NICITY                       | AND O                   | THE    | R   | RE  | PF    | 00  | UC  | T.   | VE  | . 6 | FF | E (  | :TS | <b>.</b> |   |   |   | • | •  | • | 18             |
|     |                      | 3.3.1.<br>3.3.2.                 | Oral.<br>Inhala              |                         |        |     |     |       |     |     |      |     |     |    |      |     |          |   |   |   |   |    |   | 18<br>18       |
|     | 3.4.                 | TOXICANT                         | INTER                        | ACTION                  | s.     | •   | •   | •.    | •   | •   |      | •   | •   |    |      | •   |          | • | • | • |   | •• |   | 19             |
| 4.  | CARCIN               | OGENICITY                        |                              |                         | •      |     | •   | •     | •   | • . | •    |     |     | •  |      | •   |          | • | • |   |   | •  | • | 22             |
|     | 4.1.<br>4.2.         | HUMAN DA<br>BIOASSAY             |                              |                         |        |     |     |       |     |     |      |     |     |    |      |     |          |   |   |   |   |    |   | 22<br>22       |
|     |                      | 4.2.1.<br>4.2.2.                 | Oral.<br>Inhala              | ition.                  | •      | •   | •   | •     | •   |     | •    | •   | •   | •  | •    | •   | •        | • |   |   |   |    |   | 22<br>23       |
|     | 4.3.<br>4.4.         | OTHER REWEIGHT O                 | LEVANT<br>F EVIDE            |                         | •      |     |     |       |     |     |      |     |     |    |      |     |          |   |   |   |   |    |   | 28<br>34       |
| 5.  | REGULA               | TORY STAN                        | DARDS /                      | AND CR                  | ITE    | RI  | A   | •     | •   | •   | •    | •   | •   | •  | •    | •   | •        | • |   | • | • |    | • | - 36           |
| 6.  | RISK A               | SSESSMENT                        |                              |                         | •      |     | •   | •     | •   | •   |      | •   | •   |    | •    | •   |          | • | • |   | • |    | • | 40             |
|     | 6.1.<br>6.2.<br>6.3. | SUBCHRON<br>REFERENC<br>CARCINOG | IC REFE<br>E DOSE<br>ENIC PO | RENCE<br>(RfD)<br>TENCY | D0<br> | )SE | · ( | Rf    | Ds  |     | •    | •   |     |    | •    | •   | •        |   | • |   |   | •  | • | 40<br>40<br>40 |
|     |                      | 6.3.1.<br>6.3.2.                 | Oral.<br>Inhala              | ition.                  | •      |     |     |       | •   |     |      | •   |     |    | •    | •   | •        | • | • | • |   |    | • | 40<br>41       |
| 7.  | REFERE               | NCES                             |                              |                         |        | •   |     | •     | •   | •   |      | •   |     |    | •    |     |          | • | • |   | • |    |   | 43             |
| DDF | NNTY C               | ummary Tal                       | hle for                      | Meth                    | vle    | ne  | 0   | : ከ ገ | OF  | 14  | ھا   |     |     |    |      |     |          |   |   |   |   |    |   | 62             |

# LIST OF TABLES

| No. | <u>Title</u>  | Page |
|-----|---|------|
| 2-1 | Absorption of Methylene Chloride by Human Subjects (Sedentary Conditions)   | 6    |
| 4-1 | Summary of Salivary Gland Region Sarcoma Incidence in Male Rats in a 2-Year Inhalation Study with Dichloromethane | 25   |
| 4-2 | Tumor Incidence in Rats Treated with Methylene Chloride   | 27   |
| 4-3 | Tumor Incidence in Mice Treated with Methylene Chloride   | 29   |
| 4-4 | Mutagenicity and Genotoxicity of Methylene Chloride   | 31   |
| 5-1 | Regulatory Standards and Criteria for Methylene Chloride  | 37   |

#### LIST OF ABBREVIATIONS

ADI Acceptable daily intake

CAS Chemical Abstract Service

CS Composite score

EKG Electrocardiogram

Koc Soil sorption coefficient

Kow Log octanol/water partition coefficient

LOAEL Lowest-observed-adverse-effect level

MED Minimum effective dose

NOAEL No-observed-adverse-effect level

ppm Parts per million

RfD Reference dose

RfD<sub>T</sub> Inhalation reference dose

RfDn Oral reference dose

 $RFD_S$  Subchronic reference dose

RFD<sub>SI</sub> Subchronic inhalation reference dose

RfDsn Subchronic oral reference dose

RV<sub>d</sub> Dose-rating value

RV<sub>e</sub> Effect-rating value

SCE Sister chromatid exchange

SNARL Suggested no-adverse-response level

STEL Short-term exposure limit

TLV Threshold limit value

TWA Time-weighted average

# 1. ENVIRONMENTAL CHEMISTRY AND FATE

The relevant physical and chemical properties and environmental fate of methylene chloride (CAS No. 75-09-2), also known as methylene dichloride and dichloromethane, are shown below.

| Chemical class:                       | halogenated aliphatic<br>hydrocarbon (purgeable<br>halocarbon)                         |   |
|---------------------------------------|--|---|
| Molecular weight:                     | 84.93  |   |
| Vapor pressure at 20°C:               | 362.4 mm Hg  | Callahan et al., 1979                           |
| Water solubility at 25°C:             | 13,030 mg/2  | Horvath, 1982                                   |
| Density at 20°C (reference water 4°C) | 1.3225   | Windholz, 1983                                  |
| Vapor density                         | 2.93 (air=1)   | U.S. EPA, 1985a                                 |
| Log K <sub>ow</sub> :                 | 1.25   | Hansch and Leo, 1985                            |
| K <sub>oc</sub> :                     | 27.5   | Sablic, 1984                                    |
| K <sub>oc</sub> :                     | 8.8 g/m2   | U.S. EPA, 1986b                                 |
| Bioconcentration factor:              | 2.3 [estimated from log K <sub>ow</sub> and the equation given by Veith et al. (1979)] | Veith et al., 1979                              |
|                                       | 5.25 [estimated from equation given by Veith et al. (1979)                             | U.S. EPA, 1985a                                 |
| Half-lives in air:                    | 53-127 days  | Singh et al., 1981;<br>Makide and Rowland, 1981 |
| water:                                | 1-6 days (estimated)   |   |
| Tropospheric lifetime                 | 1.4 yrs (calculated)   | Altshuller, 1980                                |
| Evaporation half-life                 | 18-25 min (experimental)<br>20.7 min (theoretical)                                     | Dilling, 1977                                   |

0.3 yrs (calculated)

0.39 yrs (calculated)

0.9±0.3 yrs (calculated) Singh et al., 1983

Cox et al., 1976

Davis et a1., 1976

Loss of methylene chloride from water will be due primarily to volatilization (Dilling, 1977; NLM, 1987). The aquatic half-life listed above was estimated from a reaeration rate ratio of 0.650 and oxygen reaeration rate constants of 0.19-0.96 day<sup>-1</sup> (Mabey et al., 1981). On prolonged contact with water, DCM hydrolyzes very slowly, forming HCl as the primary product (Fells and Moelwyn-Hughes, 1958). Adsorption to suspended solids and sediments and bioaccumulation in aquatic organisms will not be significant fate processes.

The half-life of methylene chloride in soil was not found in the available literature. Evaporation is expected to be the predominant loss mechanism from the soil surface. The evaporation half-life from soil would be expected given its larger surface area to be shorter than its evaporation half-life from water. The aqueous solubility and relatively low K value of this compound suggest that in cases where DCM is not volatilized quickly. leaching would also play a role in determining the fate of this compound in soils (NLM, 1987). In subsurface soil and sediment sampling detected DCM in 60 of 118 cases. Concentrations were from 427 to 433 ppb. Ambient soil concentrations of DCM are unknown (U.S. EPA, 1981). Biodegradation of chlorinated aliphatic hydrocarbons such as methylene chloride may be slow (Wilson et al., 1983); therefore, under conditions in which methylene chloride leaches into soil, it may leach into groundwater. "Recent evidence indicates that DCM is biodegradable under both aerobic and anaerobic conditions. Brunner and Leisinger (1978) first reported the isolation of a facultatue methylotroph with the ability to utilize DCM as a sole carbon source for growth." Wood et al. (1978) also has been able to demonstrate the degradation of DCM under anaerobic conditions. Detection of this compound in groundwater supplies supports this prediction (Page, 1981).

0028H -2- 08/14/89

However, these results are equivocal as Page (1981) does not give adequate details pertaining to the methodology used. The methodology used varies greatly and can influence the limit of detection (LOD) and accuracy and bias of results. "Contamination, absorption, and adsorption are common problems of the methods used to analyze air and water for DCM content (National Academy of Science, 1978)." However, DCM has been detected at 32 of 204 surface water sites from which samples were collected (Ewing et al., 1977).

In the atmosphere, reaction with photochemically generated hydroxyl radicals is expected to be the predominant removal mechanism (NLM, 1987; Cox et al., 1976; Davis et al., 1996). This compound may travel long distances from its emission sources because of its relatively long lifetime in the atmosphere. Based on a tropospheric to stratospheric turnover time of 30 years and a half-life of 53-127 days for methylene chloride, <1% of the tropospheric methylene chloride is expected to diffuse into the stratosphere. However, there is a great disparity in the reported residence time of DCM in the atomosphere. Cox et al. (1976) argues conunicingly for a residence time or only 0.3 years based on photo kinetiz studies. Values, however, range from the Cox et al. (1976) figure of 0.3 years to the Altoherller (1980) estimate of 1.4 years.

#### 2. ABSORPTION FACTORS IN HUMANS AND EXPERIMENTAL MAMMALS

#### 2.1. ORAL

Absorption through the intestinal mucosa appears to be fairly rapid and complete in humans (Roberts and Marshall, 1976). Prichard and Angelo (1982) have described a physiologically based pharmacokinetic model (Bishoff model) for mice and have used it to simulate the distribution. metabolism and elimination of DCM after both acute and chronic dosing. Preliminary results indicate that the kinetics depend on route and vehicle used for administration. Administration of DCM in water by oral gavage orby intravenous injection yields similar blood and tissue profiles; administration in 50% polyethylene glycol/water shows a rapid blood elimination and a slow liver elimination, while oral gavage with corn oil as a vehicle. In subsequent and more extensive investigations, Angelo et al. (1986a) administered gavage doses of 14C-methylene chloride at 50 mg/kg/day in water or 50 or 1000 mg/kg/day in corn oil once daily on 14 consecutive days to groups of six young adult male B6C3fl mice. Angelo et al. (1986b) also treated groups of six young adult male F344 rats were treated by gavage with 14C-methylene chloride at 50 or 200 mg/kg/day in water for 14 consecutive days. Cumulative 24-hour recovery of exhaled radioactivity exceeded 90% of the administered dose in both species at all dose levels, measured on days 1. 7 and 14 of treatment. These data indicate that methylene chloride is almost completely absorbed from the gastrointestinal tracts of both rats and mice.

Yesair et al. (1977) administered single gavage doses of \*\*C-methylene chloride in water or corn oil to mice and followed the appearance of radio-activity in the plasma for the following 96 hours. Plasma levels of radio-activity peaked later and higher, remaining higher throughout the experiment when the test chemical was administered in corn oil rather than in water.

Withey et al (1983) have investigated the absorption of DCM in fasting rats following oral gavage of equivalent doses (125 mg/kg) in 4 m½ of water or corn oil. The post-absorption peak blood concentration averaged three times higher for a water vehicle than for corn oil (121  $\mu$ g/m½ versus 44  $\mu$ g/m½), while the time to peak blood concentration averaged 3 times longer for corn oil than for the water vehicle (16.3 vs. 5.2 minutes). These observations suggests that gastrointestinal absorption may be greater when water is used as the vehicle. No differences in absorption rates between corn oil and water were discussed by Angelo et al. (1986a).

### 2.2. INHALATION

Riley et al. (1966) described the kinetics of absorption and excretion in a 70 kg man exposed for 2 hours to 100 ppm methylene chloride in air. As exposure progressed, the concentration in alveolar air increased, suggesting approach to steady state conditions. However, equilibrium had not been reached after 2 hours and exposure was discontinued and methylene chloride in exhaled air was monitored. The postexposure decline in concentration of methylene chloride in exhaled air appeared to be exponential and roughly proportional to the amount absorbed during the exposure period. The retention factors expressed as a percentage of inhaled dose in this and related studies are summarized in Table 2-1.

Divincenzo and Kaplan (1981) exposed groups of 4-6 volunteers to 50, 100, 150 or 200 ppm methylene chloride for 7.5 hours. Serial breath excretion curves were obtained. Pulmonary absorption was rapid during the first hour, then began to decline as steady-state was approached. Postexposure methylene chloride concentrations in exhaled air dropped rapidly. By 7 hours after treatment was terminated, expired air from those volunteers exposed to 50, 100 or 150 ppm contained <0.1 ppm methylene chloride.

TABLE 2-1
Absorption of Methylene Chloride by Human Subjects\*
(Sedentary conditions)

| Inhalation<br>Concentration<br>(ppm) | Exposure (hours) | Retention (%) | Reference                      |
|--------------------------------------|------------------|---------------|--------------------------------|
| 50                                   | 7.5              | 70            | DiVincenzo and Kaplan, 1981    |
| 100                                  | 7.5              | 60            |                                |
| 150                                  | 7.5              | 63            |                                |
| 200                                  | 7.5              | 60            |                                |
| 662                                  | 0.30             | 74            | Lehmann and Schmidt-Kehl, 1936 |
| 806                                  | 0.50             | 75            |                                |
| 1152                                 | 0.50             | 72            |                                |
| 1181                                 | 0.50             | 70            |                                |
| 44-680                               | 2.00             | 31            | Riley et al., 1966             |
| 100                                  | 2.00             | 53            | OiVincenzo et al., 1972        |
| 100                                  | 4.00             | 41            |                                |
| 200                                  | 2.00             | 51            |                                |
| 250                                  | 0.50             | 55            | Astrand et al., 1975           |
| 500                                  | 0.50             | 55            |                                |
| 750                                  | 1.00             | 34            | Engstrom and Bjurstrom, 1977   |

\*Source: U.S. EPA, 1985a

The concentration in expired air from those exposed to 200 ppm declined to 1 ppm 16 hours after treatment. Exposure and post-exposure blood concentrations of DCM were directly proportional to the magnitude of exposure (Di Vincenzo and Kalplan, 1981a).

Absorption of methylene chloride increased with duration of exposure and physical activity (presumably due to an increase in ventilation, and cardiac output) and with duratin of exposure (Astrand et al., 1975). Elevated ventilation doubled absorption but decreased retention from 55 to 40% of inhaled dose.

Engstrom and Bjurstrom (1977) demonstrated that methylene chloride absorption was related directly to degree of obesity in human subjects. Obese subjects (fat = 25% of body weight) absorbed 30% more methylene chloride than lean subjects (fat = 8% of body weight) when exposed to 750 ppm for 1 hour. Biopsy and analysis of subcutaneous fat revealed a substantial (10.2 and 8.4 mg/kg wet tissue) concentration in adiposa 1 and 4 hours postexposure, respectively. Although the concentrations in fat were somewhat lower in obese than in lean subjects, the total amount of body fat resulted in greater total methylene chloride absorption in obese subjects.

#### 3. TOXICITY IN HUMANS AND EXPERIMENTAL ANIMALS

#### 3.1. SUBCHRONIC

No reports of subchronic oral exposure of humans 3.1.1. Oral. methylene chloride have been located in the available literature. and Loeser (1967) exposed 30 male and 30 female Wistar rats for 3 months to drinking water containing 0.125 g methylene chloride/% (125 Assuming rats drink 0.049 %/day and that their average body weight is 0.35 kg, this dose corresponds to 17.5 mg/kg bw/day. No differences in behavior, appearance, body weight or survival of treated rats were observed compared with an equal number of control rats. No significant differences in hematologic values, urinalysis or plasma levels of nonesterified fatty acids were found in 8-10 male rats from each group. Blood glucose levels in 10 treated males were slightly elevated compared with 10 control males, but all values fell within the normal range. Estrous cycles, as evaluated by microscopic examination of vaginal smears, indicated no changes that were due to treatment. Necropsy and histopathological examination of ~20 animals of each sex and group revealed no lesions in any internal organ examined.

Recently, Kirschman et al. (1986) reported on groups of 20 male and 20 female Fischer 344 rats and identical numbers of B6C3Fl mice provided with drinking water containing 0, 0.15, 0.45 or 1.5% (0, 1500, 4500 or 15,000 ppm) methylene chloride for 90 days. Assuming rats drink 0.049 ½/day and that their average body weight is 0.35 kg, these doses corresponds to 0, 210, 630 or 2100 mg/kg bw/day. Assuming mice drink 0.0057 ½/day and that their average body weight is 0.03 kg, these doses correspond to 0, 285, 855 or 280 mg/kg bw/day. Slightly decreased water intake was observed in treated rats along with a slight decrease in body weights in middle-dose males and high-dose females. Minor hematological changes were observed in

rats at ≥4500 ppm and clinical chemistry parameters that reflected potentially compromised liver function were observed sporadically in all treated groups. Urinary pH was reduced in all treated groups of rats in a doserelated manner and high-dose females had elevated kidney weights. No histopathologic changes were observed in rats at an interim kill after 1 month of treatment. At termination, however, high-dose rats of both sexes and some middle-dose females had centrilobular necrosis. Dose-related increased hepatocellular vacuolization occurred in all treated groups.

Treated mice also had depressed fluid intake, and slightly reduced body weights were observed in both sexes at  $\geq 855$  mg/kg/day. There was no histopathologic evidence of toxicity in mice at an interim sacrifice performed at 1 month. At termination, a mild centrilobular fatty change, which was more apparent in males, was observed in mice at  $\geq 855$  mg/kg/day.

3.1.2. Inhalation. Inhalation exposure of humans to methylene chloride is likely to be a result of occupational exposure; consequently, long-term exposure can be expected. Studies of occupational exposure of humans to methylene chloride are discussed in Section 3.2.2. Subchronic exposure can be expected the use of consumer products containing methylene chloride, such as aerosol cans and paint stripping products. Historically, subchronic inhalation exposure of astronauts to methylene chloride vapors emanating from materials used in the interiors of spacecrafts has been a concern. Consequently, several investigators (Thomas et al., 1972; Haun et al., 1971, 1972; Weinstein et al., 1972; MacEwen et al., 1972) exposed several species of laboratory animals to atmospheric methylene chloride for up to 14 weeks. The U.S. EPA (1983) summarized results of these studies follows. Mice exposed to 25 or 100 ppm (112.9 or 451.6 mg/kg bw/day) methylene chloride continuously for 14 weeks had increases in spontaneous locomotor activity at

112.9 but not 451.6 mg/kg/day. No gross or histological lesions were found at necropsy, except that livers of mice exposed to 451.6 mg/kg/day stained Hexobarbital sleep time was unaffected, but hepatic positive for fat. levels of cytochromes were somewhat altered. Rats subjected to the same exposure regimens had nonspecific renal tubular degeneration and regeneration, and hepatic cytoplasmic vacuolization and positive fat staining at both exposure levels (55.3 and 221.3 mg/kg/day). Rats appeared to be the more sensitive species. No specific macro- or microscopic organ changes or changes in hematologic or clinical chemistry values were noted in a small number of monkeys in these studies (58.6 and 234.5 mg/kg/day). Carboxvhemoglobin levels, the result of metabolism of methylene chloride to carbon monoxide and subsequent action on hemoglobin, were elevated in monkeys at both exposure levels (58.6 and 234.5 mg/kg/day) and in dogs only at the higher exposure of 117.6 mg/kg/day but not at 29.4 mg/kg/day. There was no cumulative increase in carboxyhemoglobin over the period of exposure. overt signs of toxicity or changes in body weights relative to controls were noted in any of these four species.

Higher levels of continuous exposure were also investigated. Exposure of the same four species to 1000 or 5000 ppm (mice; 4516.2 or 22,581.2 mg/kg/day rats; 2213 or 11,067.3 mg/kg/day dog; 1176.2 or 5881.2 mg/kg/day monkeys; 2344.9 or 11,724.9 mg/kg/day) resulted in signs of severe toxicity at 5000 ppm: narcosis for the first 24 hours and pronounced lethargy for the remainder of the exposure period, reduced food consumption, and high rates of mortality in mice (22,581.2 mg/kg/day), dogs (5881.2 mg/kg/day) and monkeys. Rats were somewhat less sensitive; none died. Liver and kidney damage were common findings in all species. At 1176.2 mg/kg/day dogs were severely affected and died. Mice and rats did not show overt signs of

0028H -10- 08/14/89

toxicity, but body weight gain was slightly depressed in the rats. Less severe histopathological changes than had been seen at the highest dose were noted in the livers of all four species and in the kidneys of rats exposed to 2213.5 mg/kg/day. Monkeys showed no significant changes in hematologic or clinical chemistry values.

Male SPF Wistar rats exposed to 500 ppm (1106.7 mg/kg/day) vapors of methylene chloride for 10 days had significantly elevated liver cytochrome P-450 levels (Norpoth et al., 1974). However, this effect was not seen in animals exposed to 5000 ppm. Likewise, Weinstein et al. (1972) reported no changes in liver enzymes in mice after 28 days of exposure to 250 ppm (1129.1 mg/kg/day) methylene chloride.

Longer-term exposures to methylene chloride produces liver toxicity. ICR mice exposed to 100 ppm (451.6 mg/kg/day) methylene chloride for 10 weeks had centrilobular fat accumulation and decreased glycogen levels (Weinstein and Diamond, 1972). Inhalation of 451.6 mg/kg/day methylene chloride for 100 days produced cytoplasmic vacuolization and positive fat staining in mice (Haun et al., 1972). These effects were also observed in the liver of rats and dogs exposed to 25-100 ppm (rats; 55.3-221.3 mg/kg/day, dogs; 29.4-117.6 mg/kg/day) for 100 days. Kidney damage was also reported in this study. Rats exposed to 55.3 and 221.3 mg/kg/day methylene chloride had nonspecific renal tubular degenerative and regenerative changes.

Taken collectively, these studies suggest that subchronic exposure to methylene chloride produces behavioral effects in animals. The liver and kidneys of animals are also likely target organs for methylene chloride toxicity. Lesions in rats exposed to 25 or 100 ppm methylene chloride appear to be more severe than lesions in mice exposed to the same concentrations. Monkeys and dogs seem to be the least affected of those species

studied. At higher exposure concentrations (1176.2 mg/kg/day), dogs appear to be most sensitive and to experience treatment-related mortality.

#### 3.2. CHRONIC

3.2.1. Oral. No reports of chronic oral exposure of humans to methylene chloride have been found in the available literature. Currently a 2-year gavage study with rats has been sponsored by NTP (1988), but results are not yet available.

A 24-month toxicity and carcinogenicity bloassay was performed in F344 rats and B6C3F1 mice (NCA, 1982a,b, 1983; Serota et al., 1986a,b). Details of the experiments are discussed in Section 4.2.1. of this document. Rats and mice received doses of 0.5, 50, 125 and 250 mg/kg/day methylene chloride in their drinking water for 2 years. In rats, a statistically significant reduction in body weight, water consumption and food consumption were noted at dose levels of 125 and 250 mg/kg/day. Minimal effects were noted on the hematological and serum chemistry parameters monitored in rats. Treatment-related alterations in histomorphology were observed in rats of both sexes at all dose levels tested except the lowest. Increases in foci of cellular alterations and fatty changes were most prominent.

In mice (NCA, 1983; Serota et al., 1986b), no treatment-related changes were observed in survival, body weight, water consumption, clinical observation, leukocyte counts and gross necropsy findings. Histomorphologic alterations of the liver were observed in both male and female mice in the high-dose group.

3.2.2. Inhalation. In humans, mild intoxication by methylene chloride results in somnolence, lassitude, anorexia and mild lightheadedness, followed by greater degrees of disturbed central nervous system function and

0028H -12- 08/14/89

depression. Permanent disability has not been reported. When fatalities have occurred the cause has been attributed to cardiac injury and heart failure (NAS, 1978).

Further reports of human intoxication from methylene chloride were presented by NIOSH (1976). Most of the case reports were concerned with acute exposure and are not discussed here. Most of the epidemiologic studies lack data on the concentration of methylene chloride in breathing space air or they are complicated by exposure to other chemicals. (1987) reported that workers from several industries, including auto parts production and plastic and prosthesis manufacturing, presented a variety of CNS complaints, including headaches, dizziness, nausea, memory loss, parasthesia, tingling in the hands and feet, and loss of consciousness. These effects occurred during certain painting and cleaning operations. Methylene chloride levels up to 100 ppm were measured and the duration of exposure was 6 months to 2 years. Assuming a breathing rate of 20 m²/day, 5-day workweek, an 8-hour workday exposure and a body weight of 70 kg, this corresponds to a dose of 23.6 mg/kg/day. However, workers were also exposed concommitantly to a mixture of other chemicals and as such, the behavioral effects noted in this study cannot be unequivocally ascribed to methylene chloride.

Weiss (1967) reported a case of toxic encephalosis in a chemist exposed for several hours per day for 5 years to methylene chloride used in a salt-recrystallization operation. Measurements revealed concentrations of 660-3600 ppm (2293-12,505 mg/m³) methylene chloride in workroom air with a mean of 900 ppm (3126 mg/m³) in the breathing zone. Assuming a breathing rate of 20 m³/day, 5 day workweek, an 8 hour workday exposure, and a body weight of 70 kg, this dose corresponds to 212.7 mg/kg/day. This worker also had physical contact with liquid methylene chloride.

Exposure of 56 workers to 28-173 ppm methylene chloride (in a 9:1 methylene chloride:methanol atmosphere) resulted in statistically significant changes in mental tiredness (p<0.05) and physical tiredness and sleepiness (p<0.01) (Cherry et al., 1983). These parameters were significantly different only for the morning shift and correlated with blood carboxyhemoglobin levels at the end of the shift. Furthermore, performance deterioration on the morning shift correlated (p<0.01) with the end-of-the-shift blood concentrations of methylene chloride.

Other epidemiological studies have not revealed adverse effects in humans occupationally exposed to methylene chloride. Friedlander et al. (1978) reported an epidemiological study of male workers at Eastman Kodak exposed primarily to TWA concentrations of 30-125 ppm (104-434 mg/m<sup>2</sup>) (Assuming a breathing rate of 20 m<sup>2</sup>/day a 5-day workweek, an 8-hour workday, and a body weight of 70 kg, these doses correspond to 7.1 and 29.5 mg/kg/day) methylene chloride (estimated both from air monitoring and blood carboxyhemoglobin levels) for up to 30 years. A proportionate mortality study, where death certificates from 334 exposed workers who died from 1956-1976 were used. A cohort mortality study that involved all 751 workers employed in the exposure area in 1964 and a separate analysis of a subgroup of 252 of these workers exposed for a minimum of 20 years by 1964 were also Data from this subgroup were analyzed separately to study Derformed. effects requiring long latency periods. The follow-up period in the cohort mortality study was 13 years. Control groups consisted of other Eastman Kodak male employees working in production but not exposed to methylene chloride, New York State male cause- and age-specific mortality rates, and U.S. male age-specific mortality rates. Follow-up of workers aged >25 years was >97% as of 1964. None of these studies revealed any indication of increased risk of death from circulatory disease including ischemic heart disease, cancer or other causes.

Ott et al. (1983a) investigated mortality and current cardiac health in workers from a fiber production plant in which methylene chloride was used Given that metabolism of methylene chloride to carbon as a solvent. monoxide results in an increase in percentage of carboxyhemoglobin with a commensurate decrease in the oxygen-carrying capacity of the blood, these authors suggested that exposure to methylene chloride may lead to an increase in the incidence of ischemic cardiac disease. Data on mortality were obtained in a fiber manufacturing plant from a cohort of workers who were exposed for at least 3 months between January 1, 1954 and January 1, 1977 to a TWA of  $\sim$ 140 ppm ( $\sim$ 486 mg/m $^{2}$ ) methylene chloride. Assuming a breathing rate of 20 m³/day, a 5-day workweek, and 8-hour workday and a body weight of 70 kg, this dose corresponds to 33.1 mg/kg/day. A control cohort was composed of workers who were not exposed to methylene chloride. Another control group provided the expected death data for 5-year intervals matched by race (white and non-white) and sex. Mortality data indicated no increase in deaths in either men or women from circulatory system diseases, ischemic heart disease as a separate category, or malignant neoplasms associated with exposure to methylene chloride.

In another study of cardiac function, Ott et al. (1983b) collected 24-hour EKGs on 50 workers from two fiber producing plants. Data regarding 24 workers from the plant where exposure to TWA concentrations of 60-475 ppm (208-1650 mg/m²) (assuming a breathing rate of 20 m²/day, 5-day work-week, an 8-hour workday and a body weight of 70 kg, these doses correspond to 14.2-112.3 mg/kg/day) methylene chloride occurred were compared with data

from 26 workers from a similar plant not using methylene chloride. No significant changes in ventricular or supraventricular ectopic activity, nor episodic ST-wave segment depression were associated with exposure to methylene chloride.

Other epidemiologic studies (Skory, 1980; Skory et al., 1980a,b) apparently revealed no adverse health effects attributable to methylene chloride; however, exposure data from these studies were not available in the secondary source from which this discussion was taken.

Cherry et al. (1981) reported that a group of 46 men who were occupationally exposed to 75-100 ppm (261-347 mg/m³) (assuming a breathing rate of 20 m³/day, a 5-day workweek, an 8-hour workday and a body weight of 70 kg, these doses correspond to 17.7-23.6 mg/kg/day) methylene chloride for an unspecified length of time complained of excessive neurological symptoms. Clinical examinations, motor conduction velocity measurements, EKGs and a battery of psychological tests "designed to detect minimal brain damage" were administered to 29 of the exposed men and an equal number of age-matched unexposed men employed at similar jobs. The results revealed no evidence of cardiac abnormalities or neurological or behavioral impairment associated with exposure to methylene chloride.

Burek et al. (1980, 1984) and Dow Chemical Co. (1980) studied chronic inhalation exposure of animals to methylene chloride. Sprague-Dawley rats (SPF-derived, 129/sex/exposure concentration) and golden Syrian hamsters (~108/sex/exposure concentration) were exposed to 0, 500, 1500 or 3500 ppm (rats: 0, 197.6, 592.9 and 1383.4 mg/kg/day; hamster: 0, 288.0, 864.1 and 2016.2 mg/kg/day) methylene chloride of >99% purity. Exposures were for 6 hours/day, 5 days/week (except "holidays") for up to 2 years. Rats were subjected to interim kills at 6, 12, 15 or 18 months for cytogenetic or general chemical and histopathological examinations.

0028H

During the first week of exposure, rats in the high concentration group exhibited a slight decrease in physical activity, but appeared to return to normal activity for the remainder of the trial. During the first 2 months, rats in all groups suffered a disease believed to be sialodacryoadenitis, a transient viral involvement of the salivary glands. No increased mortality was associated with the disease. None of the exposure levels affected body weights, clinical chemistries, or hematologic or urinalysis values in rats. Carboxyhemoglobin levels ranged from 0-5.3% in controls and 8.9-20.4% in exposed rats but did not appear to be dose- or duration-related. Significant increases in mortality occurred only in the high-dose females starting at the 13th month of exposure.

Mean liver weights were increased at the 18-month interim kill, in both male and female rats in the high-dose group. Histopathologic alterations related to methylene chloride were found only in the liver. A dose-related increase in hepatocellular vacuolization, indicative of fatty degeneration, was noted in all exposed groups of rats. Multinucleated hepatocytes, a spontaneous geriatric change in female rats, were observed after 12 months in exposed and treated groups alike. A significant increase in the number of foci of altered hepatocytes was observed in high-dose females. exposed to 592.9 or 1383.4 mg/kg/day had an increased incidence of hepatocellular necrosis and coagulation necrosis. Some females exposed to 197.6 mg/kg/day ppm for 12 months appeared to have slightly increased hepatic hemosiderin. Female rats exposed to 1383.4 mg/kg/day and male rats exposed to 592.9 mg/kg/day methylene chloride had a decreased incidence or severity chronic progressive glomerulonephropathy, another normal gertatric change, compared with controls. Male rats exposed to 1383.4 mg/kg/day exhibited less severe nonrenal lesions (uremic pneumonitis, mineralization of organs and blood vessels, brain malacia, myocardial degeneration, etc.) that were associated with chronic progressive renal disease.

In this study, hamsters appeared to be less sensitive than rats to methylene chloride. Although carboxyhemoglobin levels were higher in hamsters (0.3-4.0% in control groups, 22.2-34.6% in treatment groups) than in rats, no clear evidence of toxicity was observed in hamsters. Methylene chloride-exposed hamsters exhibited a decrease in the incidence of agerelated amyloid deposition relative to controls.

# 3.3. TERATOGENICITY AND OTHER REPRODUCTIVE EFFECTS

- 3.3.1. Oral. Pertinent data associating oral exposure of humans to methylene chloride with terata or reproductive effects were not located in the available literature. The estrous cycle in female rats was reported to be unaffected by exposure to 0.125 g methylene chloride/& in their drinking water for 3 months (17.5 mg/kg/day) (Bornmann and Loeser, 1967).
- 3.3.2. Inhalation. Pertinent data regarding teratogenicity or reproductive dysfunction in humans exposed by inhalation to methylene chloride were not located in the available literature. Methylene chloride has been shown to cross the placental barrier in laboratory animals (Anders and Sunram, 1982). Schwetz et al. (1975) exposed Swiss-Webster mice and Sprague-Dawley rats to 1250 ppm methylene chloride for 7 hours/day on days 6-15 of gestation (mice, 1646.5 mg/kg/day; rats, 806.9 mg/kg/day). Mouse fetuses were collected and examined on day 18 and rat fetuses were collected and examined on day 21 of gestation. Dams of both species were minimally affected; slightly increased carboxyhemoglobin formation was the only effect reported. Delayed development (manifestations unspecified) was the only effect noted in rat fetuses. In mouse fetuses, slightly advanced ossification of the sternebrae were noted, which suggested accelerated development.

The teratogenic effect of methylene chloride in rats was also investigated by Hardin and Manson (1980). Groups of 26-28 Long-Evans hooded rats were exposed to 4500 ppm mg/m³) methylene chloride for 6 hours/day (2490.1 mg/kg/day) (group 1, before and during gestation; group 2, before gestation; group 3, during gestation). "Before gestation" exposures were the 3 weeks immediately preceding mating and "during gestation" exposures included the first 17 days of gestation. Gravida from 16-18 dams/group were examined on day 20 of gestation. A slight but significant decrease in fetal body weight occurred in groups exposed during gestation compared with controls and the group exposed only before gestation. No other abnormalities were reported. In a companion paper, Bornschein et al. (1980) studied the behavioral effects of methylene chloride on pups from 10 dams per group. Methylene chloride had no effects on behavior, body weights, food and water consumption, wheel running activity, and avoidance learning up to 400 days of age.

#### 3.4. TOXICANT INTERACTIONS

No studies of toxic interactions of methylene chloride with other xeno-biotics have been found in the available literature. Some case histories in humans, however, suggest that interactions with other compounds may occur. Functional circulatory disorders in workers exposed for >3 years to methylene chloride and other organochlorine compounds at "permissible" levels have been reported (Dunavskii, 1972). The symptoms, including chest pain, EKG irregularities, bradycardia, decreased myocardial contractility and altered adaptation to physical stress, were not attributed to methylene chloride alone.

The metabolism of methylene chloride to carbon monoxide forms the basis for concern about combined exposure to methylene chloride and carbon monoxide. Fodor and Roscovanu (1976) reported that exposure of human

subjects to 500 ppm (assuming a breathing rate of 20 m³/day, with continuous exposure, this dose corresponds to 496.3 mg/kg/day) of methylene chloride (for an unspecified duration) resulted in levels of carboxyhemoglobin in blood comparable with those produced by the TLV for carbon monoxide, 50 ppm. Mixed exposures could pose a health threat to occupationally exposed workers, smokers or cardiorespiratory patients. Savolainen et al. (1977) expressed concern that exposure to methylene choride in combination with other lipophilic solvents may result in enhanced central nervous system and metabolic effects.

Christenson and Huizinga (1971) reported the case of a 17-year-old male who died after using a mixture of 80% methylene chloride and 14.9% methanol to remove paint. Barbiturate derivatives were found in the blood, brain, urine and stomach contents. Death was ascribed to the combination of methylene chloride and barbiturates.

Two reports of phosgene poisoning related to methylene chloride (Gerritsen and Buschmann, 1960; English, 1964) pointed out that phosgene, a combustion product of methylene chloride, is highly toxic. Both cases involved the use of methylene chloride as a paint remover in an enclosed area heated with a portable kerosene heater. One case (Gerritsen and Buschmann, 1960) involved a woman who was exposed for a 3-hour period during 1 day when she was 7 months pregnant; she expectorated blood-tinged sputum and felt tightness in her chest. The next day she was hospitalized with dyspnea, cyanosis, and elevated pulse and body temperature. She was treated and discharged 8 days later. She gave birth to a healthy infant 2 months later.

The second case (English, 1964) involved a 67-year-old male who was exposed for 8 hours to methylene chloride in a small unventilated room heated with a portable kerosene heater. He experienced breathlessness, headache, giddiness and a tightness across the chest. Upon hospitalization the next day he was cyanotic, sweating, and tachypneic with extensive coarse rales in both lungs. He was discharged after 5 weeks but experienced lassitude, weakness and hypochondriosis for an additional 3 months.

#### 4. CARCINOGENICITY

#### 4.1. HUMAN DATA

Several epidemiological studies that were reviewed briefly in Section 3.2.2. examined the health effects associated with occupational exposure to methylene chloride. Friedlander et al. (1978) and Ott et al. (1983a) reported no excess cancer mortality in exposed cohorts compared with controls. This study has been recently updated through 1984 (Hearne et al., 1987). Workers were exposed to an average workplace concentration of 26 ppm (assuming a breathing rate of 20 m³/day, a 5-day workweek, an 8-hour workday and a body weight of 70 kg, this dose corresponds to 6.1 mg/kg/day) methylene chloride for an average of 22 years. Again, there was no increase in deaths from malignant neoplasms, respiratory cancer, or liver cancer in exposed workers compared with the general population. An increase in the incidence of deaths due to pancreatic cancer was observed but was not statistically significant.

#### 4.2. BIOASSAYS

4.2.1. Oral. An NTP-sponsored gavage bloassay of methylene chloride in rats is currently underway; results are not yet available (NTP, 1988).

A 24-month toxicity and carcinogenicity bioassay was performed in F344 rats (NCA, 1982a,b; Serota et al., 1986a) and B6C3F1 mice (NCA, 1983; Serota et al., 1986b). In the rat study, groups of 85 males and 85 females were administered methylene chloride in their drinking water. Target doses were 0, 5, 50, 125 or 250 mg/kg bw/day for 24 months. Consumption was monitored and actual consumption closely paralleled target doses. A second control group of 50 rats/sex and a high-dose group (250 mg/kg bw/day) of 25 rats/sex were added for 78 weeks followed by a 26-week recovery period. There was a statistically significant increase (p<0.05) in the combination of neoplastic nodules and hepatocellular carcinomas in female rats relative to controls.

These incidences (0/134, 1/85, 4/83, 1/85, 6/85 in combined control, 5, 50, 125 and 250 mg/kg bw/day groups, respectively), however, were within those observed in historical controls. The U.S. EPA (1985a) concluded therefore, that this study did not provide sufficient evidence for methylene chloride carcinogenicity in F344 rats.

In the mouse experiment, groups of 50 females and 60-200 males were treated with methylene chloride in the drinking water. Target doses were 0, 60, 125, 185 or 250 mg/kg bw/day for 24 months. Daily consumption was monitored and showed that consumed dose was similar to target dose. A significant (p<0.05) increase in the combined incidence of hepatocellular adenoma and carcinoma was recorded in male mice (24/125, 51/200, 30/100, 31/99 and 35/125 in combined control, 60, 125, 185 and 250 mg/kg bw/day groups, respectively). This data is not considered to be sufficient evidence of carcinogenicity of methylene chloride in mice.

4.2.2. Inhalation. Burek et al. (1980, 1984) and Dow Chemical Co. (1980) evaluated the carcinogenicity of methylene chloride based on a chronic (2-year) inhalation exposure regimen. Sprague-Dawley rats and golden Syrian hamsters were exposed to methylene chloride at 0, 500, 1500 or 3500 ppm 6 hours/day, 5 days/week for up to 2 years (assuming rats have a breathing rate of 0.223 m³/day and a body weight of 0.35 kg these doses correspond to 0, 197.6, 592.9 and 1383.4 mg/kg/day. Assuming a hamster has a breathing rate of 0.13 m³/day and a body weight of 0.149 kg, these doses correspond to 0,288.0, 864.1 and 2016.2 mg/kg/day. No exposure-related differences in the incidences of benign or malignant tumors were observed in male hamsters. There was a statistically significant increase (p=0.032) in the incidence of benign tumors in female hamsters exposed to 2016.2 mg/kg/day ppm methylene choride. However, this increase was attributed to increased longevity in

that group and subsequently, a higher probability of developing these tumors. After corrections for survival differences between the groups, the data is not statistically significant.

An increase in the number of benign mammary tumors per tumor-bearing rat (but not in the number of tumor-bearing rats) was observed at all dose levels in females and in males in the high dose group. There was a statistically significant increase (p<0.001) in salivery gland sarcomas in male rats given 1383.4 mg/kg/day methylene chlroide (Table 4-1). These tumors appeared to arise from mesenchymal rather than epithelial tissue. According to the investigators, interpretation of the significance of these findings is equivocal. Studies of chronic methylene chloride exposure at high levels in a wide variety of laboratory species have established the liver as the primary target organ. The apparent relationship between methylene chloride and the salivary gland was unusual and appeared to be inconsistent with previously reported data. Early in the course of treatment, these rats had apparently contracted a viral disease, sialodacryoadenitis, in the salivary glands. It was suggested that the combination of the virus with methylene chloride may have increased the incidence of salivary gland neoplasia. fact that these sarcomas appeared to arise from mesenchymal tissue rather than from epithelial (glandular) tissue further confounded interpretation. Burek et al. (1984) expected primary salivary gland neoplasms to arise from epithelial cells.

Nitschke et al. (1982) conducted a 2-year inhalation toxicity and oncogenicity study where rats were exposed to 0, 50, 200 or 500 ppm, 6 hours/day, 5 days/week for 20 (males) or 24 months (females). Assuming rats have a breathing rate of 0.223 m²/day and a body weight of 0.35 kg, these doses correspond to 0, 19.8, 79.1 and 197.7 mg/kg/day respectively. Interim

TABLE 4-1

Summary of Salivary Gland Region Sarcoma Incidence in Male Rats in a 2-Year Inhalation Study with Dichloromethanea

| Dose<br>(mg/kg/day) | Incidenceb    | Fisher's Exact Test |  |
|---------------------|---------------|---------------------|--|
| 0                   | 1/93 (15)     | NA                  |  |
| 197.6               | 0/94 (0%)     | NA                  |  |
| 592.9               | 5/91 (5.5%)   | (p≖0.10, NS)        |  |
| 1383.4              | 11/88 (12.5%) | (p=0.002)           |  |

aSource: Burek et al., 1980, 1984; Dow Chemical Co., 1980

bCochran-Armitage test for linear trend, p<0.0001

NS = Not significant; NA = not applicable

necropsies were performed at 6, 13, 15 and 18 months. No treatment-related increase in tumor incidence was observed. This study has been criticized for using doses too low to elicit a positive response. Consequently, the National Toxicology Program has performed an inhalation study in rats and mice (NTP, 1985). The final draft of this study has been released (NTP, 1986). In this experiment, 50 male and 50 female F344/N rats were exposed to air containing 0 (chamber controls), 1000, 2000 or 4000 ppm (0, 3474, 6947 or 13,894 mg/m²), 6 hours/day, 5 days/week for 102 weeks. Concurrently, 50 male and 50 female B6C3F1 mice were exposed by the same schedule to air containing 0, 2000 or 4000 ppm methylene chloride (0, 1612.9 or 3225.9 mg/kg/day). During week 3 of treatment, rats of both sexes in the 395.3 mg/kg/day group were exposed to 395.3 mg/kg/day.

In rats of both sexes, a significant increase (p<0.05 males; p<0.001 females) in mammary tumors (fibroadenoma, adenoma, fibroma: combined incidence) was observed in the high-dose groups (Table 4-2). Similarly, the incidence of subcutaneous fibroma or sarcoma (combined) according to authors, in male rats was significantly higher in the high-dose group than in controls (p<0.01). The incidence of these tumors was combined because they all occurred in the mammary chain and were considered to be of the same etiologic origin. However, combining tumor incidences is not a valid statistical procedure. Furthermore, historical incidence of these tumors, which are generally much higher than experimental controls, are generally ignored in NTP's discussion. In light of these facts the results and conclusions of the NTP (1985, 1986) bioassay are equivocal. The incidence of other tumor types were also increased although not statistically significant. These included the combined incidence of neoplastic nodules and

TABLE 4-2
Tumor Incidence in Rats Treated with Methylene Chloride<sup>a</sup>

| Tumor Type  | Historical<br>Controls <sup>e</sup> | Control    | 395.3       | 790.5       | 1581.0                   |
|---|-------------------------------------|------------|-------------|-------------|--------------------------|
| MALES   |                                     |            |             |             |                          |
| Fibroadenoma, adenoma,<br>fibroma of mammary<br>gland | >3 <u>+</u> 3%                      | 0/50 (0%)  | 0/50 (0%)   | 2/50 (4%)   | 5/50 <sup>b</sup> (10%)  |
| Subcutaneous (combined)<br>tumors of mammary area     | >5 <u>+</u> 3%                      | 1/50 (2%)  | 1/50 (2%)   | 4/50 (8%)   | 9/50 <sup>c</sup> (18%)  |
| FEMALES   |                                     |            |             |             |                          |
| fibroadenoma, adenoma,<br>fibroma of mammary gland    | >28 <u>+</u> 10%                    | 7/50 (14%) | 13/50 (26%) | 14/50 (28%) | 23/50 <sup>d</sup> (46%) |

aSource: NTP, 1986; percentages based on animal groups of 50 each.

bp<0.05; fisher's exact Test as compared to control incidences.

<sup>&</sup>lt;sup>c</sup>p<0.01 as compared to control incidences.

dp<0.001 as compared to control incidences.

eHistorical incidence +/- standard deviation (NTP studies) in 1727 animals. Historical controls were not used to derive statistical significance.

hepatocellular carcinomas in female rats, adrenal gland pheochromocytoma and interstitial cell tumors in males, squamous cell metaplasia in females, pituitary gland adenoma or carcinoma and mononuclear cell leukemias in both sexes. In male rats, the incidence of mesothelioma derived from the tunica vaginalis was found to be significantly higher in both the high and intermediate groups than in controls, but the incidence in controls in this experiment was unusually low compared with historical controls thereby making interpretation of these results equivocal.

An increase in the incidence of lung tumors in treated mice was highly significant (p<0.001) (Table 4-3). The latency period was significantly reduced in treated mice. Lung tumors were believed to be responsible for the reduced survival observed in high-dose group males and females. Also noteworthy was the incidence of liver tumors in treated mice (p=0.014 males; p<0.001 females) (see Table 4-3).

The results of the NTP (1985) bioassay were used in combination with data from the drinking water mouse study (NCA, 1983) by the U.S. EPA (1985b) to derive cancer potency estimates for oral and inhalation exposure to methylene chloride (Section 6.3.). Subsequent to the U.S. EPA (1985b) analysis, the NTP study was finalized and became available in a published form (NTP, 1986). The relevant tumor incidence data had not changed between the 1985 and 1986 versions of the study and publication of the more recent version is not expected to alter the quantitative estimation of carcinogenic potency.

### 4.3. OTHER RELEVANT DATA

Several experiments regarding the mutagenicity of methylene chloride are summarized in Table 4-4. Simmon et al. (1977) reported that methylene chloride was mutagenic to <u>Salmonella typhimurium</u> strain TA100 when assayed in a desiccator in which the atmosphere contained the test compound.

0028H -28- 08/14/89

 $\label{eq:table 4-3}$  Tumor Incidence in Mice Treated with Methylene Chloride

| Tumor Type                           | Historical <sup>e</sup><br>Controls | Control     | 1612.9<br>mg/kg/day      | 3225.9<br>mg/kg/day      |
|--------------------------------------|-------------------------------------|-------------|--------------------------|--------------------------|
| MALES                                |                                     |             |                          |                          |
| Alveolar/bronchiolar adenomas        | 17 <u>+</u> 8% <sup>f</sup>         | 3/50 (6%)   | 19/50 <sup>b</sup> (38%) | 24/50 <sup>b</sup> (48%) |
| Alveolar/bronchiolar carcinomas      | 17 <u>+</u> 8%f                     | 2/50 (4%)   | 10/50 <sup>c</sup> (20%) | 28/50 <sup>b</sup> (56%) |
| Multiple lung tumors                 |                                     | 0/50 (0%)   | 10/50 (20%)              | 28/50 (56%)              |
| Hepatocellular adenoma and carcinoma | 30 <u>+</u> 8%                      | 22/50 (44%) | 24/49 (49%)              | 33/49 <sup>c</sup> (67%) |
| depatocellular carcinoma             |                                     | 13/50 (26%) | 15/49 (31%)              | 26/49 <sup>d</sup> (53%) |
| lultiple liver tumors                |                                     | 21/50 (4%)  | 11/49 (22%)              | 16/49 <sup>c</sup> (33%) |
| EMALES                               |                                     |             |                          |                          |
| lveolar/bronchiolar adenomas         | 7 <u>+</u> 4% <sup>f</sup>          | 2/50 (4%)   | 23/48 <sup>b</sup> (48%) | 28/48 <sup>b</sup> (58%) |
| lveolar/bronchiolar carcinomas       | 7 <u>+</u> 4% <sup>f</sup>          | 1/50 (2%)   | 13/48 <sup>b</sup> (27%) | 29/48 <sup>b</sup> (60%) |
| ultiple lung tumors                  |                                     | 0/50 (0%)   | 11/48 (23%)              | 29/48 (60%)              |
| epatocellular adenoma and carcinoma  | 30 <u>+</u> 8%                      | 3/50 (6%)   | 16/48 <sup>b</sup> (33%) | 40/48 <sup>b</sup> (83%) |
| epatocellular carcinoma              |                                     | 1/50 (2%)   | 11/48 <sup>b</sup> (23%) | 32/48b (67%)             |

## TABLE 4-3 (con't)

| Tumor Type            | Historical <sup>e</sup><br>Controls | Control   | 1612.9<br>mg/kg/day | 3225.9<br>mg/kg/day |
|-----------------------|-------------------------------------|-----------|---------------------|---------------------|
| Multiple liver tumors |                                     | 0/50 (0%) | 3/48 (6%)           | 28/48 (58%)         |

aSource NTP, 1986

bp<0.001; Fisher exact test as compared to control incidence

Cp=0.014 as compared to control incidences

dp=0.005 as compared to control incidences

eHistorical incidence <u>+</u> standard deviartion (NTP) in historical controls were not used to derive statistical significance.

fCombined incidence of Alveolar/Bronchiolar Adenoma or Carcinoma.

TABLE 4-4
Mutagenicity and Genotoxicity of Methylene Chloride\*

| Assay               | Indicator<br>Organi <b>sm</b>  | Application          | Concentration or Dose         | Activating<br>System            | Response             | Comments  | Reference                    |
|---------------------|--|----------------------|-------------------------------|---------------------------------|----------------------|---|------------------------------|
| Reverse<br>mutation | Salmonella<br>typhimurium<br>TA1535, TA1537,<br>TA1538, TA98,<br>TA]00 | éxbozar.s<br>Ásbor   | 0-800 µ1/9 1<br>desiccator    | <u>+</u> S-9                    | ÷                    | Data reported only for TA100;<br>positive with or without S-9<br>activation | Simmon et al.,<br>1977       |
| Reverse<br>mutation | S. typhimurium<br>TA100  | vapor<br>exposure    | 0-1 mt/9 t<br>desiccator      | <u>+</u> S-9                    | <b>+</b>             | S-9 may enhance, but not required for mutagenicity                          | Simmon and<br>Kauhanen, 1978 |
| Reverse<br>mutation | S. typh1mur1um<br>TA1535, TA100  | exposure<br>exposure | 0-8.3% in air                 | <u>+</u> S-9                    | <b>+</b>             | S-9 enhanced mutagenicity;<br>dose-response was evident<br>in TA100         | Green, 1983                  |
| Reverse<br>mutation | S. typhimurium<br>TA1535   | sxbozace<br>Agbor    | 0-10% theo-<br>retical in air | none                            | +                    | Clear-cut dose-response clearly evident                                     | McGregor, 1979               |
| Reverse<br>mutation | <u>S. typhlmurium</u><br>TA1535, TA1537,<br>TA1538, TA98,<br>TA100     | vapor<br>exposure    | MR                            | +5-9                            | +                    | Positive result only when conducted in gas tight chamber                    | Nestmann<br>et al., 1980     |
| Reverse<br>mutation | S. <u>typhlmurlum</u><br>TA98, TA100                                   | vapor<br>exposure    | O-1 mL/<br>chamber            | <u>+</u> S-9                    | <b>+</b>             | Positive in both TA98, TA100  | Snow et al.,<br>1979         |
| Reverse<br>mutation | <u>S. typhimurium</u><br>TA98, TA100                                   | MR                   | WR                            | <b>S-9</b>                      | •                    | Data available in abstract form only  | Kanada and<br>Uyeta, 1978    |
| Reverse<br>mutation | S. <u>typhimurium</u><br>TA98, TA108                                   | vapor<br>exposure    | 0-57,000 ppm                  | <u>+</u> S- <b>9</b>            | <b>*</b>             | Response positive and dose-<br>related                                      | Jongen et al.,<br>1978       |
| Reverse<br>mutation | <u>S. typhimurium</u><br>TA1535, TA98,<br>TA100                        | exposure<br>vapor    | 0-10,000 ppm                  |                                 | <b>+</b><br><b>+</b> | Positive dose-related response only in air tight chamber                    | 8arber et al.,<br>1981       |
| Reverse<br>mutation | S. typhimurium<br>TA100  | *xposure             | 0-8.4%                        | <u>+</u> S-9                    | •                    | Positive dose-related response, S-9 activation did not enhance response     | Gr <i>e</i> en, 1980         |
| Reverse<br>mutation | <u>S. typhlmurium</u><br>TA1535, TA1537,<br>TA1538, TA98,<br>TA100     | vapor<br>exposure    | 0-750 mm/<br>desiccator       | <u>+</u> S-9                    | :                    | Weak positive response  | Gocke et al.,<br>1981        |
| Reverse<br>mutation | S. <u>typhimurium</u><br>TA100   | yapor<br>exposure    | 0-1.4%                        | ±S-9,<br>cytosał,<br>microsomes | <b>+</b><br>+        | Activation with cytosol yielded maximum response                            | Jongen et al.,<br>1982       |

TABLE 4-4 (cont.)

| Assay                             | Indicator<br>Organism                        | Application.       | Concentration or Dose                        | Activating<br>System | Response | Comments   | Reference                        |
|-----------------------------------|--|--------------------|--|----------------------|----------|--|----------------------------------|
| Rec assay                         | Bacillus<br>subtilis                         | NR                 | NR   | NR                   | -        | Bata available only in abstract form                                   | Kanada and<br>Uyeta, 1978        |
| Mitotic<br>recombination          | <u>Saccharomyces</u><br><u>cerevisiae</u> B7 | NR:                | 0-209 mH                                     | NA                   | +        | D7 strain metabolizes<br>methylene chloride to active<br>intermediates | Callen et al.,<br>1980           |
| Mitotic<br>recombination          | S. cerevistae                                | MR                 | MR   | MR                   | -        | Minimal data presented   | Simmon et al.,<br>1977           |
| Sex-linked<br>recessive<br>lethal | grosoph11a                                   | fed or<br>injected | MR   | NA                   | ~        | Votalization not prevented   | Abrahamson and<br>Valencia, 1986 |
| Sex-linked<br>recessive<br>lethal | Oresophila                                   | fed                | 0-620 <b>al</b> l                            | NA                   | •        | Conclusion; methylene chloride<br>is mutagenic to sperm                | Gocke et al.,<br>1981            |
| Sex-linked<br>recessive<br>lethal | <u>Panagrelus</u><br><u>redivivus</u>        | <b>NR</b>          | 10 <sup>-4</sup> to 10 <sup>4</sup><br>mol/s | MA                   | •        | Equivocal positive results   | Samolloff<br>et al., 1980        |
| Mutations in<br>cell-culture      | CHO and V79 colls                            | cell culture       | 0-5%   | NA                   | ~        | Equivocal negative results   | Jongen et al.<br>1981            |
| Chromosomal<br>Iberration         | rat bone<br>marrow cells                     | inhalation         | 0-3500 ррм                                   | MA                   | •        | NC   | Dow Chemical<br>Co., 1980        |
| Chromosomal<br>aberration         | MMRI mice/bone<br>marrow                     | 1.p.<br>injection  | 0-3400 mg/kg bw                              | MA                   | •        | Results equivocal  | Gocke et al.,<br>1981            |
| ister –<br>:hromatid<br>:xchange  | SCE/V79 cells                                | cell culture       | 0-4.0%                                       | NA                   | •        | Positive dose-response   | Jongen et al.,<br>1981           |
| Chromosoma]<br>Nbberation         | CHO cells                                    | cell culture       | 0-10 pt/mL                                   | <u>+</u> \$-9        | •        | Similar results in three replications                                  | Thilagar and Kumaroo, 1983       |
| ilster-<br>hromatid<br>xchange    | CHO cells                                    | dell culture       | 0-10 µt/mt                                   | <u>+</u> \$-9        | <u>.</u> | Marginal but not significant response                                  | Thilagar and<br>Kumaroo, 1983    |
| Chromosoma l<br>Naberation        | rat/mouse<br>lung/liver DNA                  | inhalation         | 4000 ppm/3 hours                             | NA                   | -        | Concluded that methylene chloride is not genotoxic                     | CEFIC, 1986                      |

<sup>\*</sup>Compound and purity not reported

MR = Not reported; NA = not applicable; NC = no comment

Metabolic activation was not required. The response was strongly doserelated. This is typical of the response of many strains of <u>S. typhimurium</u> to methylene chloride (see Table 4-4). In <u>S. cerevisiae</u> D3, however, mitotic recombination was not increased by methylene chloride (Simmon et al., 1977) although positive results were obtained in <u>S. cerevisiae</u> D7 (Callen et al., 1980). Additionally, Abrahamson and Valencia (1980) reported that methylene chloride was negative when tested for sex-linked recessive lethals in <u>Drosophila melanogaster</u>, although positive results were obtained by Gocke et al. (1981).

Thilagar and Kumaroo (1983) investigated the ability of methylene chloride to induce SCE and chromosomal aberrations in cultured Chinese hamster ovary cells. They observed extensive chromosomal aberrations, both with and without Aroclor 1242- and 1254-induced rat S-9 fraction activation. Negative results were reported in the SCE assay. These authors discovered that using plastic rather than glass for the tests markedly reduced the magnitude of the positive response. This observation suggests that methylene chloride may bind to plastic, decreasing its effective concentration in these assays.

In general, methylene chloride is mutagenic to several strains of Salmonella typhimurium. Metabolic activation with S-9 is not required but may enhance mutagenicity. Five studies reported a dose-response relationship (Green, 1980, 1983; McGregor, 1979; Jongen et al., 1978; Barber et al., 1981). The evidence for mutagenicity in other test systems is not so clear cut however. In Saccharomyces cerevisiae, an increase in mitotic recombinations were observed in the D7 strain (Callen et al., 1980) but not in the D3 strain (Simmon et al., 1977). Likewise, in Drosophila, positive (Gocke et al., 1981) and negative (Abrahamson and Valencia, 1980) results have been reported.

0028H

The mammalian cells, in vitro exposure to methylene chloride produces an increase in chromosome abberations in CHO cells (Thilagar and Kumaroo, 1983) and in sister-chromatid exchange in SCE/V79 cells (Jongen et al., 1981). However, other reports are negative or equivocal (Jongen et al., 1981; Dow Chemical Co., 1980; Goche et al., 1981; Thilagar and Kumaroo, 1983).

The <u>in vivo</u> interaction of methylene chloride and its metabolites with F344 rat and B6C3Fl mouse lung and liver DNA was measured after inhalation of 4000 ppm <sup>14</sup>C-methylene chloride for 3 hours (CEFIC, 1986). The DNA was isolated from the tissue 6, 12 and 24 hours after the start of exposure and then analyzed for total radioactivity and the distribution of radioactivity in enzymatically hydrolyzed DNA samples. Low-levels of radioactivity were found in DNA from the lungs and livers of both rats and mice. Higher levels were found in mouse DNA and protein than in the rat. The radioactivity was found to be associated with normal constituents of DNA. Under the conditions of this study, there was no evidence for alkylation of DNA by methylene chloride and it was concluded that methylene chloride was not genotoxic (CEFIC, 1986).

There is clear evidence of mutagenicity in yeast. Results are mixed for <u>Drosophila</u> and mammalian cells in cultures, and were largely negative in mammalian cells <u>in vivo</u>. Given this evidence it was concluded that methylene chloride may be a weak mutagen in mammalian systems (U.S. EPA, 1987).

## 4.4. WEIGHT OF EVIDENCE

Pertinent data regarding carcinogenicity of methylene chloride in humans were not located in the available literature. An NTP-sponsored gavage study in rats is currently underway, but results are not yet available (NTP, 1988). Burek et al. (1980, 1984) was unable to demonstrate carcinogenicity

0028H -34- 08/14/89

in rats with chronic inhalation exposure to high levels 1383.4 mg/kg/day methylene chloride. Another NCI bioassay that involved inhalation exposure has recently been published (NTP, 1985, 1986). The results indicate that methylene chloride is may be carcinogenic to rats (mammary tumors) and mice (lung and liver tumors). However, questionable statistical assumptions used in deriving carcinogenic incidences makes the NTP (1985, 1986) conclusions equivocal. Applying the criteria for evaluating the overall weight of evidence of carcinogenicity to humans adopted by the Carcinogen Assessment Group of the U.S. EPA (1986a), methylene chloride is most appropriately classified a B2 - Probable Human Carcinogen. This classification is consistent with the current analysis of the U.S. EPA (1985a, 1986c).

#### 5. REGULATORY STANDARDS AND CRITERIA

Pertinent regulatory standards and criteria for methylene chloride are summarized in Table 5-1. According to the ACGIH (1986) the TLV committee adopted a TLV-TWA of 100 ppm in the workplace. The committee recommends the elimination of the STEL until additional toxicological data and industrial hygiene experience become available.

The NIOSH (1976) occupational criteria for methylene chloride was set at a TWA of 75 ppm for a 10-hour workday, 40-hour workweek. Recognizing the additional relationship between methylene chloride and carbon monoxide, a formula has been derived to relate methylene chloride toxicity and carbon monoxide toxicity with concentrations that are >9 ppm.

$$[C(CO) + L(CO)] + [C(DCM) + L(DCM)] < 1$$

where

C(CO) = TWA concentration of carbon monoxide (ppm)

L(CO) = 35 ppm, the recommended TWA limit for carbon monoxide

C(DCM) = TWA concentration of methylene chloride (ppm)

L(DCM) = 75 ppm, the recommended TWA limit for methylene chloride

The carcinogenic response to methylene chloride has been documented in several studies of chronic effects in animals, (see Section 4.2.1.). Consequently, a recent report by NIOSH (1986) recommends that methylene chloride be regarded as a "potential occupational carcinogen". Therefore, NIOSH (1986) recommends that occupational exposure to methylene chloride be controlled to the lowest feasible limit.

The U.S. EPA (1986c) has verified an oral slope factor of  $7.5\times10^{-2}$  (mg/kg/day)<sup>-1</sup> and a drinking water unit risk of  $2.1\times10^{-7}$  ( $\mu$ g/2). An inhalation slope factor of  $1.4\times10^{-2}$  (mg/kg/day)<sup>-1</sup> and an inhalation unit risk of  $4.1\times10^{-6}$  ( $\mu$ g/m<sup>2</sup>)<sup>-1</sup>. These values were derived using a linearized multistage procedure.

TABLE 5-1
Regulatory Standards or Criteria for Methylene Chloride<sup>a</sup>

| Standard or Criteria   | Value  | Reference                    |
|--|--|------------------------------|
| TLV-TWA  | 100 ppm (~360 mg/m³)   | ACGIH, 1986                  |
| Level in spice oleo-resins   | 30 mg/kg   | NIOSH, 1976                  |
| Level in decaffeinated<br>coffee   | 10 mg/kg   |                              |
| B-hour PEL-TWA<br>Acceptable ceiling<br>Maximum peak                                   | 500 ppm (1737 mg/m³)<br>1000 ppm (3474 mg/m³)<br>2000 ppm (6948 mg/m³) | OSHA, 1986                   |
| Ambient water quality criterion Ingesting water and organisms Ingesting organisms only |  | U.S. EPA, 1980a              |
| Health advisories (HAs) 1-day (child) 10-day (child) DWELD                             | 13.3 mg/1<br>1.5 mg/1<br>1.75 mg/1                                     | U.S. EPA, 1985c              |
| Suggested no adverse response<br>level (SNARL)<br>l-day<br>7-day                       | 45.5 mg/1.<br>6.5 mg/1.  | U.S. EPA, 19850<br>NAS, 1980 |

<sup>&</sup>lt;sup>a</sup>See discussion in text for concurrent exposure to carbon monoxide.

bowEL = drinking water equivalent level.

As an oil and fat solvent, methylene chloride is allowed in spice oleoresins at concentrations up to 30 mg/kg and in decaffeinated coffee at concentrations up to 10 mg/kg (NIOSH, 1976).

OSHA (1986) has established Permissible Exposure Limits (PELs) for occupational exposures to methylene chloride as follows: 8-hour TWA, 500 ppm; acceptable ceiling concentration, 1000 ppm; acceptable maximum peak > ceiling (5 minutes in any 2 hours), 2000 ppm.

The U.S. EPA (1980a) has set the ambient water quality criterion for ingesting water and organisms at 0.19  $\mu g/2$  and for ingesting organisms only at 15.7  $\mu g/2$ .

The U.S. EPA Office of Drinking Water (ODW) has prepared health advisories (HAs) for a number of drinking water contaminents. The HAs describe concentrations of contaminents in drinking water at which non-carcinogenic effects would not be anticipated to occur and would provide a margin of safety to protect sensitive members of the population. The 1-day and 10-day HAs are calculated for exposure of children; for methylene chloride these values are 13.3 and 1.5 mg/2, respectively (U.S. EPA, 1985c). Adequate data for calculating a longer-term HA were not available, however, IRIS reports a modified DWEL value of 0.5 mg/2 as the longer-term HA. Since methylene chloride is classified by EPA is a B2 carcinogen, a lifetime HA value is not recommended. However, a drinking water equivalent level (DWEL) of 1.75 mg/2 is recommended.

The U.S. EPA (1985c) has recalculated previously published 1- and 7-day suggested-no-adverse-response level (SNARL) data (NAS, 1980). These values are 45.5 and 6.5 mg/%, respectively. Because of a lack of suitable data, a chronic SNARL was not calculated.

The U.S. EPA (1985d) has verified a chronic RfD $_0$  of 6x10 $^{-2}$  mg/kg/day for methylene chloride based on NOAELs of 5.85 and 6.47 mg/kg/day for male and female rats, respectively. The data was derived from a 2-year drinking water bioassay (NCA, 1983; Serota et al., 1986a,b). However, since the supporting data base is limited, the confidence in the RfD $_0$  is only medium.

### 6. RISK ASSESSMENT

# 6.1. SUBCHRONIC REFERENCE DOSE (RfDs)

Methylene chloride has been demonstrated to probably be carcinogenic in both rats and mice. Data are sufficient for estimating carcinogenic potency.

6.2. REFERENCE DOSE (RFD)

Methylene chloride has been demonstrated to probably be carcinogenic in both rats and mice. Data are sufficient for estimating carcinogenic potency.

6.3. CARCINOGENIC POTENCY  $(q_1*)$ 

- 6.3.1. Oral. In the 2-year NCA studies (NCA, 1982a,b, 1983; Serota et al., 1986a,b), F344 rats and B6C3F1 mice were administered methylene chloride in the drinking water. Female rats had an increased incidence of neoplastic nodules or hepatocellular carcinomas, which was significant when compared with matched but not historical controls. No increased incidence of liver tumors was reported in male rats. Male mice had increased incidences of combined neoplastic nodules and hepatocellular carcinomas; however, these increases were not statistically significant or dose-related.
- \_ U.S. EPA (1985b) derived a drinking water unit risk estimate of  $2.1x10^{-7} (uq/2)^{-1}$ based on extrapolation usina the linearized multistage model. The slope factor is an arithmetic mean of slope factors derived from the NTP (1985) inhalation study and the NCA (1983) oral data. This value was verified by the U.S. EPA (1986c) and is available on IRIS. This analysis of the NTP inhalation study is discussed more fully in Section 6.3.2. According to the analysis presented by U.S. EPA (1986c), methylene chloride is absorbed rapidly following either inhalation or oral exposure. Therefore, use of inhalation data for calculation of risk from oral exposure is possible if lung tumor data are omitted. Further details of the assumptions and derivation of the oral unit risk for humans are presented in the

U.S. EPA (1986c) summary. Methylene chloride was considered to be a well absorbed vapor at low doses. The unit risk should not be used if the water concentration exceeds  $5x10^4$  µg/2, because above this concentration the slope factor may differ from that stated.

Subsequent to the derivation of the U.S. EPA (1985b) analysis, the NTP data became available in a final form (NTP, 1986). The NTP (1986) data did not differ from the 1985 version and there has been no modification of the The value of  $2.1\times10^{-7}$  (ug/1)<sup>-1</sup> is equivalent to risk assessment.  $7.5 \times 10^{-3}$  (mg/kg/day)<sup>-1</sup>, which is adopted as the estimate of the carcinogenic potency to orally exposed humans for the purposes of this document. 6,3.2. Inhalation. The U.S. EPA (1985b) used the data from the 2-year inhalation study reported by NTP (1985) for combined carcinomas and adenomas of the lung or liver in B6C3F1 mice for derivation of the inhalation unit risk of  $4.1x10^{-6}$  (µg/m³). Details of the NTP (1985) study, as well as other inhalation studies are discussed in Section 3.2.2. of this document, and assumptions and derivation of the inhalation unit risk are presented in the U.S. EPA (1985b) document. As discussed in Section 6.3.1., the NTP data are available in a final form (NTP, 1986), which does not differ substantially from the 1985 version and there is no modification to this risk assessment based upon this final NTP report. The above value is equivalent to  $1.4 \times 10^{-2}$  (mg/kg/day)<sup>-1</sup> and is verified and available on IRIS (U.S. EPA, 1986c). The value of  $1.4\times10^{-2}$  (mg/kg/day)<sup>-1</sup> is adopted for the purposes of this document as the estimate of the carcinogenic potency of methylene chloride to humans exposed by inhalation. The unit risk should not be used if the air concentration exceeds 2x10° µg/m² because above this concentration the slope factor may differ from that stated.

After critical analysis of the evidence, EPA has concluded that methylene chloride may be a weak genotoxicant in mammals (U.S. EPA, 1987). Current evidence is not sufficient to identify the mechanism of action or to indicate that this mechanism would not be expected in humans. Indeed, it seems reasonable to assume that humans metabolize methylene chloride via the glutathion-s-transferase pathway as do rats and mice, albeit at a much slower rate. U.S. EPA (1987) suggests that since some data exist on the pharmacokinetics and metabolic pathways of methylene chloride, it may be more appropriate to use a physiologically based, pharmacokinetic model (Andersen et al., 1987). However, this model has not been fully validated.

Nevertheless, using the pharmacokinetic model with its original kinetic parameters to estimate the internal dose of the glutathion-s-transferase metabolite, and correcting internal dose for interspecies differences in sensitivity by using the surface area correction factor, leads to a unit risk estimate for continuous inhalation exposure to 1  $\mu g/m^2$  of 4.7x10<sup>-7</sup>. This factor is ~8.7-fold lower than the inhalation unit risk of 4.1x10<sup>-6</sup> derived from the 2-year NTP (1986) bioassay. This difference, in light of the uncertainties of the model mentioned above, are not, in practical terms, very distinct. In this case, pharmacokinetic considerations have not revealed a great error inherent in using applied dose as a surrogate for internal or delivered dose.

#### 7. REFERENCES

Abrahamson, S. and R. Valencia. 1980. Evaluation of substances of interest for genetic damage using <u>Drosophila melanogaster</u>. Prepared for FDA Contract 233-77-2119. (Cited in U.S. EPA, 1985a)

ACGIH (American Conference of Governmental and Industrial Hygienists).

1986. Documentation of the Threshold Limit Values and Biological Exposure
Indices for Substances in Workroom Air, 5th ed. Cincinnati, OH.

Ahshuller, A.P. 1980. Lifetimes of organic molecules in the troposphere and lower atmosphere. Adv. Environ. Sci. Technol. 10: 181-219. (Cited in U.S. EPA, 1985a)

Andersen, M.E., H.J. Clewell, III., M.L. Gargas, F.A. Smith and R.H. Reitz. 1987. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87: 185-205.

Angelo, M.J., A.B. Pritchard, D.R. Hawkins, A.R. Waller and A. Roberts. 1986a. The pharmacokinetics of dichloromethane. I. Disposition in B6C3F1 mice following intravenous and oral administration. Food Chem. Toxicol. 24(9): 965-974.

Angelo, M.J., A.B. Pritchard, D.R. Hawkins, A.R. Waller and A. Roberts. 1986b. The pharmacokinetics of dichloromethane. II. Disposition in Fischer 344 rats following intravenous and oral administration. Food Chem. Toxicol. 24(9): 975-980.

0028H

Anders, M.W. and J.M. Sunram. 1982. Transplacental passage of dichloromethane and carbon monoxide. Toxicol. Lett. 12(4): 231-234. (Cited in ATSDR, 1987)

Astrand, I., P. Ovrum and A. Carlsson. 1975. Exposure to methylene chloride--I. Its concentration in alveolar air and blood during rest and exercise and it metabolism. Scand. J. Work Environ. Health. 1: 78-94. (Cited in U.S. EPA, 1985a)

ATSDR (Agency for Toxic Substances and Disease Registry). 1987. Toxico-logical Profile for Methylene Chloride. Draft.

Barber, E.D., W.H. Donish and K.R. Mueller. 1981. A procedure for the quantitative measurement of volatile liquids in the Hines <u>Salmonella/micro-some assay</u>. <u>In</u>: 11th Ann. Meeting Environ. Mutagen. Soc. p. 39. (Cited in U.S. EPA, 1985a)

Bornmann, G. and A. Loeser. 1967. Zur Frage winer Cronisch-Toxichen Wirkung von Dichlormethan. Z. Lebensmittle-Unters. Forsch. 136: 14. (Ger.) (Cited in U.S. EPA, 1983)

Bornschein, R.L., L. Hastings and J. Manson. 1980. Behavioral toxicity in the offspring of rats following maternal exposure to dichloromethane. Toxicol. Appl. Pharmacol. 52(1): 29-37. (Cited in U.S. EPA, 1985a)

Brunner, W. and T. Leisinger. 1978. Bacterial degradation of dichloromethane. Experientia. 34: 16-71. (Cited in U.S. EPA 1985a) Burek, J.D., K.D. Nitschke, T.J. Bell, et al. 1980. Methylene Chloride: A Two-Year Inhalation Toxicity and Oncogenicity Study in Rats and Hamsters. Final Report. Toxicology Reseach Laboratory, Health and Environmental Sciences, Dow Chemical USA, Midland, MI 48640. Co-sponsored by Diamond Shamrock Corp., Dow Chemical Co., Imperial Chemical Industry Ltd., Stauffer Chemical Co., and Vulcan Materials Co. (Cited in U.S. EPA, 1985a)

Burek, J.D., K.D. Nitschke, T.J. Bell, et al. 1984. Methylene choride: A two-year inhalation toxicity and oncogenicity study in rats and hamsters. Fund. Appl. Toxicol. 4(1): 30.

Callahan, M.A., M.W. Slimak, N.W. Gabel, et al. 1979. Water-Related Environmental Fate of 129 Priority Pollutants. Vol. II. Office of Water Planning and Standards, Office of Water and Waste Management, U.S. EPA, Washington, DC. EPA 440/4-79-029b.

Callen, D.F., C.R. Wolf and R.M. Philpot. 1980. Cytochrome P<sub>450</sub>-mediated genetic activity and cytotoxicity of seven halogenated aliphatic hydrocarbons in <u>Saccharomyces cerevisiae</u>. Mutat. Res. 77: 55-63. (Cited in U.S. EPA, 1985a)

CEFIC (European Center of Chemical Manufacturer's Federation). 1986. T. Green, W.M. Provan, D.C. Collinge and A.E. Guest: Methylene chloride: Interaction with the rat and mouse liver and lung DNA <u>in vivo</u>. ICI Central Toxicology Laboratory, Report No. CTL/R/851. January 22. (Cited in ATSDR, 1987)

Cherry, N., H. Venables, H.A. Waldron and G.G. Wells. 1981. Some observations on workers exposed to methylene chloride. Br. J. Ind. Med. 38(4): 351-355. (Cited in U.S. EPA, 1983)

Cherry, N., H. Venable, H.A. Waldron. 1983. The acute behavioral effects of solvent exposure. J. Soc. Occup. Med. 33: 13-18. (Cited in ATSDR, 1987)

Christenson, E.K.J. and T. Huizinga. 1971. A fatal case of methylene chloride intoxication. Pharm Weekblad. (Dut.) 106: 301-05. (Cited in NIOSH, 1976)

Cox, R.A., R.C. Denwent, A.E.J. Eggleton and J.E. Lovelock. 91976. Photochemical oxication of halocarbons in the troposphere. Atmos. Environ. 10: 305-308.

Davis, D.D., G. Machado, B. Conaway, Y. Oh and R. Watson. 1976. A temperature dependent Kinetics study of the reaction of OH with  $CH_CCI$ ,  $CH_2CI_2$  and  $CH_3$ . Br. J. Chem. Phys. 65(4): 1268-1274. (Cited in U.S. EPA, 1985a)

Dilling W.L. 1977. Interphase transfer processes. II. Evaporation rates of chloroimethanes, ehtanes, ethylene, propanes and propylenes from dilute aqueous solutions. Comparisons with theoretical predictions. Environ. Sci. Technol. 11(4): 405-409. (Cited in U.S. EPA, 1985a)

Divincenzo, G.D. and C.J. Kaplan. 1981. Uptake, metabolism and elimination of methylene chloride vapor by humans. Toxicol. Appl. Pharmacol. 59: 130-140.

DiVincenzo, G.D., F.J. Yanno and B.D. Astill. 1972. Human and canine exposures to methylene chloride vapor. Am. Ind. Hyg. Assoc. J. 33: 125-135. (Cited in U.S. EPA, 1985a)

Dow Chemical Co. 1980. Methylene Chloride. A two-year inhalation toxicity and oncogenicity study in rats and hamsters. FYI-OTS-0281-0097. Follow-up response A. U.S. EPA, Office of Toxic Substances, Washington, DC. (Cited in U.S. EPA, 1985a,b)

Dunavskii, G.A. 1972. Functional condition of circulatory organs in workers employed in the production of organochlorine compounds. Gig. Tr. Prof. Zabol. 16: 48. (Rus.) (Cited in U.S. EPA, 1980a)

English, J.M. 1964. A case of probable phosgene poisoning. Br. Med. J. 1: 38. (Cited in NIOSH, 1976)

Engstrom, J. and R. Bjurstrom. 1977. Exposure to methylene chloride. Content in subcutaneous adipose tissue. Scand. J. Work Environ. Health. 3: 215-224. (Cited in U.S. EPA, 1985a)

Ewing B.B., E.S.K. Chian, T.C. Cook, C.A. Evans, P.K. Hopke and E.G. Perkins. 1977. Monitoring to detect previously unrecognized pollutants in surface waters. EPA 560/6-77-015, July. (Cited in U.S. EPA, 1985a)

Fells, I. and E.A. Moelwyn-Hughes. 1958. The kinetics of the hydrolysis of methylene chloride. J. Chem. Soc. (London) p. 1326-1333. (Cited in U.S. EPA, 1985a)

Filippova, L.M., et al. 1967. Chemical mutagens. IV. Mutagenic activity of geminal system. Genetika. 8: 134. (Cited in U.S. EPA. 1980a)

Fodor, G.G. and A. Roscovanu. 1976. Increased blood-CO-content in humans and animals by incorporated halogenated hydrocarbons. Zentralbl. Bakteriol. (Orig B). 162: 34. (Ger.) (Cited in U.S. EPA, 1980a)

Friedlander, B.R., T. Hearne and S. Hall. 1978. Epidemiologic investigation of employees chronically exposed to methylene chloride. J. Occup. Med. 20: 657-666. (Cited in U.S. EPA, 1985a)

Gerritsen, W.B. and C.H. Buschmann. 1960. Phosgene poisoning caused by the use of chemical paint removers containing methylene chloride in ill-ventilated rooms heated by kerosene stoves. Br. J. Ind. Med. 17: 187-189. (Cited in NIOSH, 1976)

Gocke, E., M.T. King, K. Eckhardt and D. Wild. 1981. Mutagenicity of cosmetics ingredients licensed by the European communities. Mutat. Res. 90: 91-109. (Cited in U.S. EPA, 1985a)

Green T. 1980. The metabolism and mutagenicity of methylene chloride. Abstracts of papers, Society of Toxicology, Inc. 19th annual meeting, Washington, DC, March 9-13, 1980. (Cited in U.S. EPA, 1985a)

Green, T. 1983. The metabolic activation of dichloromethane and chloro-fluoromethane in a bacterial mutation assay using <u>Salmonella typhimurium</u>. Mutat. Res. 118(4): 277-288.

Hansch, C. and A.J. Leo. 1985. MedChem Project Issue No. 26. Pomona College, Claremont, CA.

Hardin, B.D. and J.M. Manson. 1980. Absence of dichloromethane teratogenicity with inhalation exposure to rats. Toxicol. Appl. Pharmacol. 52(1): 22-28. (Cited in U.S. EPA. 1981)

Haun, C.C., E.S. Harris and K.I. Darmer. 1971. Continuous animal exposure to methylene chloride. AMRL-TR-71-120, No. 10. <u>In</u>: Proceedings of the Second Annual Conference on Environmental Toxicology, Wright Patterson Air Force Base, OH. p. 125-135. (Cited in U.S. EPA, 1983)

Haun, C.C., E.H. Vernot, K.I. Darmer, Jr. and S.S. Diamond. 1972. Continuous animal exposure to low levels of dichloromethane. AMRL-TR-130, Paper No. 12. <u>In</u>: Proceedings of the Third Annual Conference on Environmental Toxicology, Wright Patterson Air Force Base, OH, Aerospace Medical Research Laboratory. p. 199-208. (Cited in U.S. EPA, 1983)

Hearne, F.T., F. Grose, J.W. Pifer, B.R. Friedlander and R.L. Raleigh. 1987. Methylene chloride mortality study: dose-response characterization and animal model comparison. J. Occup. Med. 29: 217-228. (Cited in ATSDR, 1987)

Horvath, A.L. 1982. Halogenated Hydrocarbons. Solubility Miscibility with Water. Marcel and Dekker Inc., NY. p. 484.

Jongen, W.M.F., G.M. Alink and J.H. Koeman. 1978. Mutagenic effect of dichloromethane on <u>Salmonella typhimurium</u>. Mutat. Res. 56: 245. (Cited in U.S. EPA, 1980a)

Jongen, W.M.F., P.H.M. Lohman, M.J. Kettenhagen, G.M. Alink, F. Berends and J.H. Koeman. 1981. Mutagenicity testing of dichloromethane in short-term mammalian test systems. Mutat. Res. 8(2): 203-213.

Jongen, W.M.F., E.G.M. Harmsen, G.M. Alink and J.H. Koeman. 1982. The effects of glutathione conjugation and microsomal oxidation on the mutagenicity of dichloromethane in <u>Salmonella</u> <u>typhimurium</u>. Mutat. Res. 95(2-3): 183-189.

Kanada, T. and M. Uyeta. 1978. Mutagenic screening of organic solvents in microbial systems. Mutat. Res. 54: 215. (Abstract) (Cited in U.S. EPA, 1985a)

Kirschman, J.C., N.M. Brown, R.H. Coots and K. Morgareidge. 1986. Review of investigations of dichloromethane metabolism and subchronic oral toxicity as the basis for the design of chronic oral studies in rats and mice. Food Chem. Toxicol. 24(9): 943-949.

Lehmann, K.B. and L. Schmidt-Kehl. 1936. The thirteen most important chlorinated aliphatic hydrocarbons from the standpoint of industrial hygiene. Arch. Hyg. 116: 131-268. (Cited in U.S. EPA, 1985a)

Mabey, W.R., J.H. Smith, R.T. Podoll, et al. 1981. Aquatic Fate Process

Data for Organic Priority Pollutants. Monitoring and Data Support Division,

Office of Water Regulations and Standards, Washington, DC. EPA 440/4-81-014.

MacEwen, J.D., E.H. Vernot and C.C. Haun. 1972. Continuous Animal Exposure to Dichloromethane. AMRL-TR-72-28, Systemed Corporation Report No. 2-71005. Wright Patterson Air Force Base, OH, Aerospace Medical Research Laboratory. 33 p. (Cited in U.S. EPA, 1983)

Makide, Y. and F.S. Rowland. 1981. Tropospheric concentrations of methyl chloroform,  $CH_3CCl_3$  in January, 1978 and estimates of the atmospheric residence times for halocarbons. Proc. Natl. Acad. Sci. 78: 5953-5937.

McGregor, D.B. 1979. Practical experience in testing unknowns <u>in vitro</u>.

<u>In</u>: Topics in Toxicology. Mutagenesis in Submammalian Systems: Status and Significance, G.E. Paget, Ed. University Park Press, Baltimore, MD. p. 53-71. (Cited in U.S. EPA, 1985a)

NAS (National Academy of Sciences). 1978. Nonfluorinated halomethanes in the environment. Washington, DC. (Cited in U.S. EPA, 1980a)

NAS (National Academy of Sciences). 1980. Drinking water and Health. Vol. 3. Washington, DC: National Academy Press. (Cited in ATSDR, 1987)

NCA (National Coffee Association). 1982a. 24-Month chronic toxicity and oncogenicity study of methylene chloride in rats. Final report. Prepared by Hazleton Laboratories America, Inc., Vienna, VA, (Aug. 16, 1982). Unpublished. (Cited in U.S. EPA, 1985a)

0028H -51- 08/07/89

NCA (National Coffee Association). 1982b. 24-Month chronic toxicity and oncogenicity study of methylene chloride in rats. Addition to the final report. Prepared by Hazleton Laboratories America, Inc., Vienna, VA (Nov. 5. 1982). Unpublished. (Cited in U.S. EPA, 1985a)

NCA (National Coffee Association). 1983. 24-Month chronic toxicity and oncogenicity study of methylene chloride in mice. Final report. Prepared by Hazleton Laboratories America, Inc., Vienna, VA (Nov. 30, 1982). Unpublished. (Cited in U.S. EPA, 1985a,d, 1986c)

Nestmann, E.R., E.G.-H. Lee, T.I. Matula, G.R. Douglas and J.C. Mueller. 1980. Mutagenicity of constituents identified in pulp and paper mill effluents using the <u>Salmonella/mammalian microsome assay</u>. Mutat. Res. 79: 203-212. (Cited in U.S. EPA, 1985a)

NIOSH (National Institute for Occupational Safety and Health). 1976. Criteria for a Recommended Standard...Occupational Exposure to Methylene Chloride. U.S. DHEW Publ. No. 76-138. U.S. DHEW, Cincinnati, OH.

NIOSH (National Institute for Occupational Safety and Health). 1986. Current Intelligence Bulletin 46. Methylene chloride. U.S. DHHS. Publ. No. 86-114. U.S. DHHS, Cincinnati, OH.

Nitschke, K.D., T.J. Bell, L.W. Rampy and M.J. Mckenna. 1982. Methylene Chloride. A two-year inhalation toxicity and oncogenicity study in rats. Toxicology Research Laboratory, Health and Environmental Sciences. Dow Chemical Co., Midland, MI (October 11, 1983). (Cited in U.S. EPA, 1985a,b)

0028H -52- 08/14/89

NLM (National Library of Medicine). 1987. Hazardous Substance Data Bank.
Report No. 66. Computer Printout.

Norpoth, K., U. Witting, M. Springoram and C. Witting. 1974. Induction of microsomal enzymes in the rat liver by inhalation of hydrocarbon solvents. Int. Arch. Arbeitmed. 33(4): 315-321. (Cited in ATSDR, 1987)

NTP (National Toxicology Program). 1985. NTP technical report on the toxicology and carcinogenesis studies of dichloromethane in F344/N rats and B6C3F1 mice/inhalation studies). February. NTP TR 306. Board draft.

NTP (National Toxicology Program). 1986. Toxicology and carcinogenesis studies of dichloromethane (methylene chloride) (CAS No. 75-09-2) in F344/N rats and B6C3F1 mice (inhalation studies). NTP, PHS, NIH, Research Triangle Park, NC. TR No. 306. NIH No. 86-2562.

NTP (National Toxicology Program). 1988. Management Status Report produced from NTP Chemtrack System: Data received up to 01/14/88. NTP, Research Triangle Park, NC.

OSHA (Occupational Safety and Health Administration). 1986. Occupational exposure to methylene chloride. Federal Register. 51: 42257.

Ott, M.G., L.K. Skory, P.R. Williams, J.M. Bronson and B.B. Holder. 1983a. Health surveillance of employees occupationally exposed to methylene chloride. I. Mortality. Scand. J. Work Environ. Health. 9: 8-16. (Cited in U.S. EPA, 1985a)

Ott, M.G., L.K. Skory, P.R. Williams, J.M. Bronson and B.B. Holder. 1983b. Health surveillance of employees occupationally exposed to methylene chloride. Twenty-four hour electrocardiographic monitoring. Scand. J. Work Environ. Health. 9: 26-30. (Cited in U.S. EPA, 1985a)

Page, G.W. 1981. Comparison of groundwater and surface water for patterns and levels of contamination by toxic substances. Environ. Sci. Technol. 15: 1475-1481.

Pritchard, A. and M.J. Angelo. 1982. Comparative pharmacokinetic studies of methylene chloride in oil versus drinking water. Report commissioned by National Coffee Association of U.S.A. Inc. (Cited in U.S. EPA, 1985a)

Riley, E.C., D.W. Fassett and W.L. Sutton. 1966. Methylene chloride vapor in expired air of human subjects. Am. Ind. Hyg. Assoc. J. 27: 341-348. (Cited in U.S. EPA, 1985a)

Roberts, C.J.C. and F.P.F. Marshall. 1976. Recovery after "lethal" quantity of paint remover. Br. Med. J. 6000: 20-21. (Cited in U.S. EPA, 1985a)

Sabljic, A. 1984. Predictions of the Nature and Strength of Soil Sorption of Organic Pollutants by Molecular Topology. J. Agric. Food Chem. 32: 243-246.

Samoiloff, M.R., S. Schulz, Y. Jordan, K. Denich and E. Arnott. 1980. A rapid simple long-term toxicity assay for aquatic contaminants using the nematode, <u>Panagrellus redivivus</u>. Can. J. Fish Aquat. Sci. 37: 1167-1174. (Cited in U.S. EPA, 1985a)

Savolainen, H., P. Pfaffli, M. Tengen and H. Vainio. 1977. Biochemical and behavioral effects of inhalation exposure to tetrachloroethylene and dichloromethane. K. Neuropath. Exptl. Neurol. 36(6): 941-949. (Cited in U.S. EPA, 1985a)

Schwetz, B.A., B.K.J. Leong and P.J. Gehring. 1975. The effect of maternally inhaled trichloroethylene, perchloroethylene, methyl chloroform and methyl chloride on embryonal and fetal development in mice and rats. Toxicol. Appl. Pharmacol. 32: 84. (Cited in U.S. EPA, 1980a)

Serota, D.G., A.K. Thakur, B.M. Ulland, et al. 1986a. A two-year drinking water study of dichloromethane in rodents. I. Rats. Food Chem. Toxicol. 24: 951-958.

Serota, D.G., A.K. Thakur, B.M. Ulland, et al. 1986b. A two-year drinking water study of dichloromethane in rodents. II. Mice. Food Chem. Toxicol. 24: 959.

Simmon, V.F. and K. Kauhanen. 1978. <u>In vitro</u> microbological mutagenicity assays of 2-chlorethyl chloroformate. Final report, Contract 68-03-11-74. Prepared for U.S. EPA, National Environmental Research Center, Water Supply Laboratory, Cincinnati, OH 45268. (Cited in U.S. EPA, 1985a)

Simmon, V.F., V. Kauhanen and R.G. Tardiff. 1977. Mutagenic activity of chemicals identified in drinking water. <u>In</u>: Progress in Genetic Toxicology, S. Scott, et al., Ed. (Cited in U.S. EPA, 1985a)

0028H -55- 08/07/89

Singh, H.B., L.J. Salas, A.J. Smith and H. Shigeishi. 1981. Measurements of some potentially hazardous organic chemicals in urban atmospheres. Atmos. Environ. 15: 601-612.

Singh, H.B., L.J. Salas and R.E. Stiles. 1983. Selected man-made halogenerated chemicals in the air and oceanic environment. T. Geophys. Res. 88: 3675-3683. (Cited in U.S. EPA, 1985a)

Skory, L.K. 1980. Health surveillance of employees occupationally exposed to methylene chloride. V. A review of effects on oxygen transport. Scand. J. Work Environ. Health. (In press) (Cited in Burek et al., 1980; U.S. EPA, 1983)

Skory, L.K., M.G. Ott, P.R. Williams, J.M. Bronson and B.B. Holder. 1980a. Health surveillance of employees occupationally exposed to methylene chloride. III. Clinical pathological evaluation. Scand. J. Work Environ. Health. (In press) (Cited in Burek et al., 1980; U.S. EPA, 1983)

Skory, L.K., M.G. Ott, P.R. Williams, J.M. Bronson and B.B. Holder. 1980b. Health surveillance of employees occupationally exposed to methylene chloride. IV. 24-Hour EKG monitoring. Scand. J. Work Environ. Health. (In press) (Cited in Burek et al., 1980; U.S. EPA, 1983)

Snow, L., P. McNair and B.C. Castro. 1979. Mutagenesis testing of methylene chloride and 1,1,1-trichloroethane in <u>Salmonella</u> strains TA-100 and TA-98. Personal Communication from Northrop Services, Inc., P.O. Box 12313, Research Triangle Park, NC, 27709, September 19. (Cited in U.S. EPA, 1985a)

Thilagar, A.K. and V. Kumaroo. 1983. Induction of chromosome damage by methylene chloride in CHO cells. Mutat. Res. 116(3-4): 361-367.

Thomas, A.A., M.K. Pinkerton and J.A. Warden. 1972. Effects of low level dichloromethane exposure on the spontaneous activity of mice. AMRL-TR-72-130, Paper No. 14. <u>In</u>: Proceedings of the Third Annual Conference on Environmental Toxicology, Wright Patterson Air Force Base, OH, Aerospace Medical Research Laboratory. p. 223-227. (Cited in U.S. EPA, 1985a)

- U.S. EPA. 1980a. Ambient Water Quality Criteria Document for Halomethanes. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Water Regulations and Standards, Washington, DC. EPA-440/5-80-051. NTIS PB 81-117624.
- U.S. EPA. 1980b. Guidelines and Methodology Used in the Preparation of Health Effects Assessment Chapters of the Consent Decree Water Criteria

  Documents. Federal Register. 45(231): 79347-79357.
- U.S. EPA. 1982. Errata: Halomethanes Ambient Water Quality Criteria for the Protection of Human Health. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Water Regulations and Standards, Washington, DC.
- U.S. EPA. 1983. Reportable Quantity for Dichloromethane. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Emergency and Remedial Response, Washington, DC.

0028H -57- 08/14/89

- U.S. EPA. 1984. Methodology and Guidelines for Ranking Chemicals Based on Chronic Toxicity Data. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH. for the Office of Emergency and Remedial Response, Washington, DC.
- U.S. EPA. 1985a. Health Assessment Document for Dichloromethane (Methylene Chloride). Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Research Triangle Park, NC. EPA-600/8-82-004F. NTIS PB 85-191559.
- U.S. EPA. 1985b. Addendum to the Health Assessment Document for Dichloro-methane (Methylene Chloride): Updated Carcinogen Assessment of Dichloro-methane (Methylene Chloride). Office of Health and Environmental Assessment, Carcinogen Assessment Group, Washington, DC.
- U.S. EPA. 1985c. Health Advisory for Dichloromethane. Draft. Environmental Protection Agency, Office of Drinking Water, Washington. DC
- U.S. EPA. 1985d. Integrated Risk Information System (IRIS). Reference dose (RfD) for oral exposure for methylene chloride. On-Line. (Verification date 11/6/85.) Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH.
- U.S. EPA. 1986a. Guidelines for Carcinogen Risk Assessment. Federal Register. 51(185): 33992-34003.

U.S. EPA. 1986b. Superfund Public Health Evaluation Manual. Office of Emergency and Remedial Response, Washington, D.C. EPA 540/1-86-060.

U.S. EPA. 1986c. Integrated Risk Information System (IRIS). Carcinogenicity Assessment for Lifetime Exposure to Methylene Chloride. On-line. (Verification date 12/04/86.) Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH.

U.S. EPA. 1987. Update to the Health Assessment Document and Addendum for dichloromethane. Review Draft. EPA 600/8-87/030A.

Veith, G.D., D.L. Defoe and B.V. Bergstedt. 1979. Measuring and estimating the bioconcentration factor of chemicals in fish. J. Fish Res. Board Can. 36: 1040-1048.

Weinstein, R.S., D.D. Boyd and K.C. Back. 1972. Effects of continuous inhalation of dichloromethane in the mouse-morphologic and functional observations. Toxicol. Appl. Pharmacol. 23: 660. (Cited in U.S. EPA, 1981, 1985a)

Weinstein, R.S. and S.S. Diamond. 1972. Hepatotoxicity of dichloromethane (methylene chloride) with continuous inhalation exposure at a low dose level. Proc. 3rd Ann. Conf. Env. Toxicol. Aerospace Med. Res. Lab. Wright-Patterson Air Force Base, Ohio. AMRL-TR-72-130. p. 209-220. (Cited in ATSDR, 1987)

Weiss, G. 1967. Toxic encephalosis as an occupational hazard with methylene chloride. Zentralbl Arbeitsmed. 17: 282-285. (Ger.) (Cited in NIOSH, 1976)

Welch, L. 1987. Reports of clinical disease secondary to methylene chloride exposure -- A collection of 141 cases. Unpublished study. Submitted to OPTS/EPA 3/31. (Cited in ATSDR, 1987)

Wilson, J.T., J.F. McNabb, B.H. Wilson and M.J. Noonan. 1983. Biotransformation of selected organic pollutants in groundwater. Dev. Ind. Microbiol. 24: 225-233.

Windholz, M., Ed. 1983. The Merck Index, 10th ed. Merck and Co., Inc., Rahway, NJ.

Withey, J.R., B.T. Collins and P.G. Collins. 1983. Effect of vehicle on the pharmacokinetics and uptake of four halogenated hydrocarbons from the gastrointestinal tract of the rat. T. Appl. Toxical. 3(5): 249-253. (Cited in U.S. EPA, 1985a)

Wood, G.D., K.J. Maule and C.J. Petrocelli. 1979. An evaluation of using partition coefficients and water solubility to estimate bioconcentration factors for organic chemicals in fish. <u>In</u>: Aquatic Toxicology, J.G. Eaton, P.R. Parrish and A.C. Hendricks, Ed. American Society for Testing and Materials. p. 116-129. (Cited in U.S. EPA, 1985a)

Yesair, D.W., D. Jaques, P. Schepis and R.H. Liss. 1977. Dose-related pharmacokinetics of (14C) methylene chloride in mice. Fed. Proc. Fed. Am. Soc. Exp. Biol. 36: 988 (Abstr. No. 3836). (Cited in Kirschman et al., 1986)

<sup>†</sup>Arithmetic mean of slope factors derived from NTP (1986) and the NCA (1983) data.